aminoglutethimide has been researched along with Breast Cancer in 447 studies
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer." | 10.16 | Tamoxifen therapy of metastatic breast cancer. ( Manni, A, 1987) |
| "ABCSG-06 investigated the efficacy of tamoxifen vs tamoxifen plus aminoglutethimide in postmenopausal women with hormone receptor-positive breast cancer." | 9.17 | Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. ( Balic, M; Dubsky, P; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kwasny, W; Mlineritsch, B; Moik, M; Pfeiler, G; Ploner, F; Renner, K; Samonigg, H; Sandbichler, P; Seifert, M; Selim, U; Singer, C; Steger, GG; Stöger, H, 2013) |
| "The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifen-based therapy." | 9.13 | Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. ( Dietze, O; Filipits, M; Gnant, MF; Greil, R; Grill, R; Huynh, A; Jakesz, R; Kwasny, W; Lax, S; Lehnert, M; Rudas, M; Schippinger, W; Singer, C; Stierer, M; Stiglbauer, W, 2008) |
| "3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0." | 9.12 | Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. ( Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C, 2007) |
| "To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer." | 9.10 | Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Schmid, M; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Taucher, S; Tausch, C; Wette, V, 2003) |
| "The study compares letrozole (Femara and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with anti-estrogens." | 9.09 | [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, Kh; Friedrich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, NO; Reichard, P; Romieu, G, 1999) |
| "The efficacy of combined endocrine therapy with tamoxifen (TAM), aminoglutethimide (AG), and hydrocortisone (H) or tamoxifen and fluoxymesterone (FLU) was evaluated against treatment with tamoxifen alone in 311 patients above 65 years of age with a first recurrence of a metastatic breast cancer." | 9.09 | Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. ( Andersen, J; Andersson, M; Bastholt, L; Christensen, IJ; Dombernowsky, P; Kamby, C; Mouridsen, HT; Munkholm, P; Møller, KA; Rose, C, 2000) |
| "Three hundred eighty postmenopausal breast cancer patients receiving adjuvant tamoxifen treatment for 3 years were randomized to either continue tamoxifen for 2 more years or to switch to low-dose aminoglutethimide (250 mg daily) for 2 years." | 9.09 | Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. ( Amoroso, D; Boccardo, F; Caroti, C; Cruciani, G; Farris, A; Mesiti, M; Mustacchi, G; Romeo, D; Rubagotti, A; Schieppati, G; Villa, E, 2001) |
| "One hundred and twelve post menopausal or post oophorectomy women with advanced breast cancer (BC) who had all previously had aminoglutethimide (AG) were treated with the potent aromatase inhibitor 4-hydroxy androstenedione (4-OHA)." | 9.08 | Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. ( Murray, R; Pitt, P, 1995) |
| "Trilostane and aminoglutethimide, both given with a physiological replacement dose of hydrocortisone, were randomly allocated to 112 eligible patients with postmenopausal advanced breast cancer." | 9.08 | Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. ( Bachelot, F; Barley, VL; Blackledge, GR; Dermaille, A; Fargeot, P; Namer, M; Pouillart, J; Rowland, CG; Tyrrell, CJ; Williams, CJ, 1995) |
| "We studied the clinical and endocrine effects of the aromatase inhibitor formestane (4-hydroxyandrostenedione, 4-OHA) in heavily pretreated breast cancer patients (median number of previous endocrine treatments 2, range 1-4)." | 9.08 | Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. ( Anker, G; Geisler, J; Johannessen, DC; Lønning, PE, 1996) |
| "A phase III randomized trial was performed to determine whether combination hormonal therapy with aminoglutethimide (AG) and hydrocortisone (HC) plus megestrol acetate (MA) improved response rates, response duration, or increased survival over the sequential use of each hormone in women with estrogen receptor-positive metastatic breast cancer (MBC) who had maintained stable disease for at least 6 months or responded to tamoxifen." | 9.08 | Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. ( Budd, GT; Congdon, JE; Green, SJ; Hynes, HE; Martino, S; O'Sullivan, J; Osborne, CK; Russell, CA, 1997) |
| "In a European multicentre phase II study, 80 postmenopausal patients (pts) with advanced breast cancer progressing on aminoglutethimide (AG) at daily doses of > or = 500 mg were enrolled." | 9.08 | Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. ( Bonneterre, J; di Salle, E; Lanzalone, S; Murray, R; Paridaens, R; Piscitelli, G; Roché, H; Serin, D; Thürlimann, B; Zurlo, MG, 1997) |
| "The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens." | 9.08 | Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G, 1998) |
| "Aminoglutethimide (Ag) is a potent aromatase-enzyme inhibitor used in the treatment of patients with breast cancer." | 9.07 | Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer. ( Carella, MJ; Dimitrov, NV; Gossain, VV; Rovner, DR; Srivastava, L, 1994) |
| "Trilostane and Aminoglutethimide, each given with a physiological replacement dose of hydrocortisone, were randomly allocated to 72 eligible postmenopausal advanced breast cancer patients; following treatment failure on either drug the patient continued with the other drug, if in a suitable clinical condition." | 9.07 | Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. ( Barley, VL; Blackledge, GR; Rowland, CG; Tyrrell, CJ; Williams, CJ, 1993) |
| "Tamoxifen and aminoglutethimide are two hormone therapies reported to be effective palliative approaches for patients with metastatic breast cancer." | 9.07 | Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. ( Andersen, JW; Cummings, FJ; Davis, TE; Gale, KE; Horton, J; Mansour, EG; Smith, TJ; Tormey, DC; Wolter, JM, 1994) |
| "In a randomized trial of second line hormone therapy 56 postmenopausal women with advanced breast cancer received low dose aminoglutethimide (AGT) 125 mg twice daily without hydrocortisone (27 patients), or hydrocortisone (HC) 20 mg twice daily (29 patients)." | 9.07 | Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. ( Bates, T; Coltart, RS; Ebbs, SR; Fraser, SC; Mercer, PM, 1993) |
| "The study purpose was to evaluate aminoglutethimide (AG) as adjuvant therapy in patients with primary node-positive breast cancer in a randomized double-blind placebo-controlled trial." | 9.07 | Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. ( Coombes, RC; Easton, D; Ford, HT; Jones, AL; Law, M; McKinna, JA; Nash, A; Powles, TJ; Smith, IE; Tidy, A, 1992) |
| "The clinical and biochemical effects of combined treatment with the two aromatase inhibitors aminoglutethimide and 4-hydroxyandrostenedione were evaluated in 10 patients suffering from advanced breast cancer." | 9.07 | Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. ( Dowsett, M; Ekse, D; Jacobs, S; Johannessen, DC; Jones, A; Lønning, PE; McNeil, F; Powles, TJ, 1992) |
| "A randomized study comparing low-dose aminoglutethimide (AG) with and without hydrocortisone (HC) was performed to investigate whether corticosteroid replacement contributes to the therapeutic effects of the drug administered as a front-line endocrine therapy in postmenopausal advanced breast cancer." | 9.07 | Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. ( Bacchi, M; Bisagni, G; Boni, C; Brugia, M; Carpi, A; Ceci, G; Cocconi, G; Di Costanzo, F; Franciosi, V; Gori, S, 1992) |
| "One hundred and twenty patients with metastatic breast cancer, whose disease progressed on hormonal therapy with tamoxifen, were treated with aminoglutethimide." | 9.06 | Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. ( Biran, S; Brufman, G, 1990) |
| "In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared." | 9.06 | Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989) |
| "One hundred and one postmenopausal patients with advanced breast cancer were enrolled in a randomized phase II clinical trial to investigate the clinical and hormonal response to aminoglutethimide administered at daily doses of 2 x 125 mg, 3 x 125 mg or 2 x 250 mg, with no addition of hydrocortisone." | 9.06 | Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Bonfrer, JM; Bruning, PF; de Jong-Bakker, M; Hart, AA; Moolenaar, AJ; Nooijen, WJ; van der Linden, E, 1989) |
| "The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer." | 9.06 | Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986) |
| "Three hundred and twenty-two postmenopausal patients with primary breast cancer and ipsilateral axillary node involvement were randomized to receive aminoglutethimide and hydrocortisone or placebo for 2 years in a double blind randomized trial between April 1980 and March 1985." | 9.06 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. ( Bradbeer, J; Chilvers, C; Coombes, RC; Easton, D; Ford, HT; McKinna, A; Powles, TJ; Smith, IE; White, H; Yarnold, J, 1987) |
| "Fifty postmenopausal women with advanced breast cancer were included in the following randomized phase II trial: 25 patients received aminoglutethimide 1000 mg and hydrocortisone 40 mg daily." | 9.06 | A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer. ( Gennatas, CS; Kalovidouris, A; Kouvaris, J; Papavasiliou, C; Paraskevas, GA; Trichopoulos, D, 1987) |
| "222 patients with disseminated breast cancer have been randomised to receive either a combination of hormone therapies using tamoxifen, aminoglutethimide with hydrocortisone, and danazol (TAD), or tamoxifen alone." | 9.05 | Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. ( Ashley, S; Coombes, RC; Ford, HT; Gazet, JC; Nash, AG; Neville, AM; Powles, TJ, 1984) |
| "A group of 122 postmenopausal patients with histologically proven node-positive primary breast cancer have been randomized to receive aminoglutethimide-hydrocortisone or placebo aminoglutethimide-placebo hydrocortisone for 2 years." | 9.05 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. ( Bettelheim, R; Chilvers, C; Coombes, RC; Dowsett, M; Ford, HT; Gazet, JC; Gordon, C; Powles, TJ; Smith, IE; Zava, D, 1982) |
| "The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid." | 9.05 | Aminoglutethimide dose and hormone suppression in advanced breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983) |
| "The endocrine effects of replacement doses of hydrocortisone in postmenopausal women with advanced breast cancer were compared with the same doses of hydrocortisone plus aminoglutethimide." | 9.05 | Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1984) |
| "Aminoglutethimide inhibited adrenal steroid synthesis, as assessed by serial estimations of plasma dehydroepiandrosterone sulphate in ten patients with advanced breast cancer." | 9.05 | Aminoglutethimide therapy in advanced breast cancer. ( Anderson, JL; Black, RB; Phillipou, G, 1981) |
| "Thirty-eight patients with advanced breast cancer, resistant to prior endocrine therapy and in most cases prior chemotherapy, were treated with aminoglutethimide, 250 mg qds." | 9.05 | The treatment of metastatic breast cancer with aminoglutethimide. ( Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1981) |
| "Tamoxifen (TAM), a standard endocrine treatment for advanced breast cancer, probably acts by competing for the estrogen receptor protein in the breast tumor cells." | 9.05 | Tamoxifen and aminoglutethimide in advanced breast cancer. ( Ascoli, DM; Corkery, J; Gelman, RS; Henderson, IC; Hourihan, J; Leonard, RC; Salhanick, HA, 1982) |
| "Sixty-six post-menopausal women with metastatic breast cancer were randomised to receive tamoxifen or tamoxifen with aminoglutethimide." | 9.05 | A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer. ( Calman, K; Campbell-Ferguson, J; Habeshaw, T; Kaye, S; Macbeth, F; Milsted, R; Sangster, G; Smith, D, 1985) |
| "Aminoglutethimide, a drug known to block adrenal steroidogenesis and peripheral aromatization of androgens to estrogens, has been found effective in the treatment of breast cancer." | 9.05 | Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer. ( Ardizzoni, A; Conte, P; Lionetto, R; Pronzato, P; Rosso, R, 1985) |
| "The response rate of advanced postmenopausal breast cancer patients to treatment with aminoglutethimide (AG) + danazol was significantly worse than that with AG alone." | 9.05 | Antagonism of aminoglutethimide and danazol in the suppression of serum free oestradiol in breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Murray, RM; Pitt, P, 1985) |
| "During the last decade aminoglutethimide has been recognised as a valuable alternative in endocrine therapy for advanced breast cancer." | 8.77 | Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. ( Kvinnsland, S; Lønning, PE, 1988) |
| "Aminoglutethimide is an effective treatment for advanced postmenopausal breast cancer, acting in a novel way." | 8.77 | Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review. ( Harris, AL, 1985) |
| "Approximately one third of human breast carcinomas are hormone dependent and regress upon reduction of circulating estrogen levels." | 7.76 | Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors. ( Brodie, AM; Santen, RJ, 1986) |
| "The results of treatment of 959 breast cancer patients by AG and glucocorticoids in several studies are reviewed." | 7.75 | [Chemical adrenalectomy induced by aminoglutethimide in the treatment of breast cancer. A review]. ( Cikes, M, 1983) |
| " The aim of this paper was to study if a melatonin pretreatment prior to aminoglutethimide increases the efficiency of the aromatase inhibitor used in treating breast cancer." | 7.73 | Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2005) |
| " Treatment with the aromatase inhibitor aminoglutethimide increases the concentration of gamma-glutamyl transpeptidase (gamma-GT) in breast cancer patients." | 7.70 | Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients. ( Berge, R; Berntsen, H; Ekse, D; Johannessen, DC; Lønning, PE; Netteland, B; Svardal, A, 1998) |
| "In this study, we evaluated the effect of estrogen suppression with three aromatase inhibitors, aminoglutethimide (n = 30), formestane (n = 12), and exemestane (n = 10), and the progestin megestrol acetate (n = 21) on plasma total homocysteine (tHcy) in patients suffering from advanced breast cancer." | 7.70 | Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. ( Anker, GB; Johannessen, DC; Lien, EA; Lonning, PE; Refsum, H; Ueland, PM, 1999) |
| "54 patients (pts) with metastatic breast cancer were treated with aminoglutethimide 250 mg p." | 7.69 | [Use of aminoglutethimide in the hormonal treatment of patients with advanced breast cancer]. ( Czech, I; Dziewulska-Bokiniec, A; Wojtacki, J, 1994) |
| "The effects of treatment with the aromatase inhibitors aminoglutethimide (AG) and formestane or the synthetic progestin megestrol acetate (MA) on plasma levels of insulin-like growth factor I (IGF-1), IGF-II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status were investigated in 39 patients suffering from advanced breast cancer." | 7.69 | Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. ( Frost, VJ; Helle, SI; Holly, JM; Lønning, PE; van der Stappen, JW, 1996) |
| "Twenty-eight and 24 patients with advanced breast cancer were treated with Aminoglutethimide (AG) or AG + Tamoxifen (AG + TAM) from June 1984 to June 1989, respectively." | 7.68 | [Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer]. ( Hisamatsu, K; Nomura, Y; Tashiro, H, 1992) |
| "The influence of the prototype aromatase inhibitor Aminoglutethimide (AG) and its analogue Rogletimide (RG) on peripheral aromatisation were investigated in 13 postmenopausal women with advanced breast cancer." | 7.68 | The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. ( Dowsett, M; Jacobs, S; Jones, AL; Lønning, PE; MacNeill, FA; Powles, TJ, 1992) |
| "Plasma insulin-like growth factor-I (IGF-I) was measured in breast cancer patients before and during treatment with tamoxifen, goserelin or aminoglutethimide." | 7.68 | Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. ( Aakvaag, A; Johannessen, DC; Lien, EA; Lønning, PE, 1992) |
| "Aminoglutethimide is effective in the treatment of breast cancer in postmenopausal patients as a result of its inhibition of aromatase." | 7.68 | Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. ( Cantwell, BM; Dowsett, M; Harris, AL; Mehta, A, 1991) |
| "44 postmenopausal women with progressive soft tissue, osseous and/or pleuropulmonal metastases of breast cancer were treated with aminoglutethimide (Rodazol) and hydrocortisone." | 7.68 | [Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer]. ( Brockmann, B; Geschke, E; Schmidt, UM, 1991) |
| "Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND)." | 7.68 | Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. ( Ashley, SE; Coombes, RC; Ellin, CL; Hardy, JR; Judson, IR; Powles, TJ; Sinnett, HD, 1990) |
| "The clinical and endocrine effects of low-dose aminoglutethimide without hydrocortisone in patients with advanced breast cancer were investigated." | 7.67 | Low-dose aminoglutethimide in treatment of advanced breast cancer. ( Bozek, T; Carr, L; Dowsett, M; Gazet, JC; Jeffcoate, SL; Kurkure, A; McKinna, JA; Smith, IE; Stuart-Harris, R, 1984) |
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 7.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 7.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "Thirty-one postmenopausal patients with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1 000 - 1 250 mg/d) plus hydrocortisone replacement." | 7.67 | Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment. ( Bezwoda, WR; Browde, S; Derman, DP; Goss, G; Lange, M, 1984) |
| "A 67-year-old patient with breast carcinoma on treatment with aminoglutethimide (AG) developed profound leukopenia and sepsis." | 7.67 | Aminoglutethimide-induced leukopenia: a case report and review of the literature. ( Gez, E; Sulkes, A, 1984) |
| "In a phase II clinical trial, 38 postmenopausal women with advanced breast cancer were treated with aminoglutethimide and replacement hydrocortisone." | 7.67 | Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer. ( Bonfrèr, JG; Bruning, PF; de Jong-Bakker, M; Engelsman, E; Hamersma-vd Linden, E; Nooyen, W, 1984) |
| "Aminoglutethimide (AG) was administered as palliative therapy in 112 patients with metastatic breast cancer." | 7.67 | Aminoglutethimide in patients with metastatic breast cancer. ( Dao, TL; Nemoto, T; Patel, JK; Rosner, D, 1989) |
| "Plasma level, plasma clearance, production rate and interconversions of oestrone and oestrone sulphate were measured in six breast cancer patients receiving aminoglutethimide therapy." | 7.67 | Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. ( Johannessen, DC; Lønning, PE; Thorsen, T, 1989) |
| "In an attempt to define the activity and toxicity of low-dose aminoglutethimide plus steroid replacement in advanced breast cancer, we treated 40 patients with aminoglutethimide 500 mg/day + hydrocortisone 50 mg/day." | 7.67 | Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies. ( Ambroso, G; Crivellari, D; Frustaci, S; Galligioni, E; Gasparini, G; Lo Re, G; Monfardini, S; Talamini, R; Vaccher, E, 1989) |
| "From July 1980 to June 1983, 61 postmenopausal women with progressive metastatic breast cancer were treated with aminoglutethimide, 250 mg 4 times daily, plus cortisone acetate, 25 mg twice daily." | 7.67 | Aminoglutethimide in advanced breast cancer. ( Bella, M; Bisagni, G; Ceci, G; Cocconi, G; Passalacqua, R, 1985) |
| "One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)." | 7.67 | Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986) |
| "We analyzed the results of clinical studies on the therapeutic efficacy of hormone monotherapy with tamoxifen, medroxyprogesterone acetate, and aminoglutethimide in metastatic breast cancer, which were published between 1971 and 1986 and involved altogether 7000 patients." | 7.67 | On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. ( Petru, E; Schmähl, D, 1987) |
| "5 mg, twice a day) aminoglutethimide (AG), without hydrocortisone (HC), escalating at monthly intervals to a conventional dose of AG (500 mg twice a day) combined with HC, were studied in 33 postmenopausal breast cancer patients." | 7.67 | Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. ( D'Souza, A; Donaldson, A; Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE; Stuart-Harris, R, 1985) |
| "Sixty patients suffering from metastatic breast cancer, whose disease progressed on chemotherapy and/or hormonal therapy with tamoxifen, were treated with aminoglutethimide." | 7.67 | Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen. ( Biran, S; Brufman, G, 1985) |
| "Seventy-two women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone (AG)." | 7.67 | Aminoglutethimide as second line therapy in advanced breast cancer. ( Blomqvist, C; Elomaa, I; Rissanen, P, 1986) |
| "We treated 21 patients with advanced breast cancer with buserelin, aminoglutethimide and cortisone acetate in an attempt to obtain a complete estrogen blockade both in premenopausal and postmenopausal patients." | 7.67 | Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations. ( Ferrari, V; Marini, G; Marpicati, E; Montini, E; Moretti, R; Simoncini, E; Zaniboni, A, 1988) |
| "In this small study, the effect of aminoglutethimide on the disposition of oestrogens in women with advanced breast cancer was investigated using bolus injections of 4-[14C]-oestradiol and 6,7-[3H]-oestrone sulphate, alone or in combination." | 7.67 | Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. ( Kvinnsland, S; Lønning, PE; Thorsen, T; Ueland, PM, 1987) |
| "This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer." | 7.67 | Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987) |
| "Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%." | 7.67 | [The use of aminoglutethimide (orimeten) in disseminated breast cancer]. ( Bassalyk, LS; Garin, AM; Lichinitser, MR; Nadezhdina, TM; Vyshinskaia, GV, 1987) |
| "Seventy-nine postmenopausal patients received aminoglutethimide (AG; 750 mg daily) and hydrocortisone therapy for metastatic or locally recurrent breast cancer following the failure of other hormonal therapy." | 7.67 | Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity. ( Gilmore, OJ; Plowman, PN; Rowell, NP, 1987) |
| "In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%)." | 7.67 | Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status. ( Bezwoda, WR; Browde, S; Dansey, RD; Hesdorffer, CS, 1987) |
| "Aminoglutethimide (AG) is now an established agent for producing a 'medical adrenalectomy' in patients with breast cancer." | 7.67 | Aminoglutethimide therapy in breast cancer: relationship of blood levels to drug-related side effects. ( Boucher, AE; Demers, LM; Santen, RJ, 1987) |
| "Eighty-seven consecutive patients with metastatic breast cancer were treated with aminoglutethimide plus hydrocortisone." | 7.67 | Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments. ( Bonadonna, G; Brambilla, C; Tancini, G; Zambetti, M, 1987) |
| "The pharmacokinetics of the optical enantiomers of warfarin (R-warfarin and S-warfarin) were investigated in patients treated for breast cancer with aminoglutethimide (AG)." | 7.67 | The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer. ( Kvinnsland, S; Lønning, PE; Ueland, PM, 1986) |
| "Aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily was used to treat 76 postmenopausal women with advanced breast cancer." | 7.67 | Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Cantwell, BM; Dawes, PJ; Evans, RG; Farndon, J; Harris, AL; Needham, G; Sainsbury, JR; Wilson, R, 1986) |
| "In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation." | 7.67 | Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986) |
| "Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus replacement dose hydrocortisone." | 7.67 | Role of aminoglutethimide in male breast cancer. ( Dowsett, M; Harris, AL; Smith, IE; Stuart-Harris, R, 1986) |
| "A clinical phase II study was performed to evaluate the therapeutic efficacy of simultaneously administered aminoglutethimide and polychemotherapy in 31 patients with predominant bone metastases of breast cancer." | 7.67 | [Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer]. ( Dabag, S; Rieche, K; Scharlau, L, 1986) |
| "Only 13% of postmenopausal advanced breast cancer patients responded to endocrine treatment with aminoglutethimide plus danazol whilst 33% responded to aminoglutethimide alone, despite a similar suppression of serum oestradiol levels in the two groups." | 7.67 | Biochemical basis for the antagonism between aminoglutethimide and danazol in the endocrine treatment of breast cancer. ( Dowsett, M; Jeffcoate, SL; Murray, RM; Pitt, P, 1986) |
| "Eighteen premenopausal patients with progressive metastatic breast cancer were treated with aminoglutethimide (AG)/cortisone." | 7.67 | Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1986) |
| "Serum aminoglutethimide (AG) and N-acetylaminoglutethimide (NAG) concentrations were measured by high pressure liquid chromatography (HPLC) in 24 postmenopausal women with advanced breast cancer receiving increasing doses of oral AG." | 7.67 | Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer. ( Bradbrook, I; Morrison, P; Rogers, HJ; Smith, IE; Stuart-Harris, R, 1985) |
| "Aminoglutethimide without glucocorticoid has been shown to be a clinically effective treatment for postmenopausal breast cancer in low dosage (250 mg day-1)." | 7.67 | Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Santen, RJ; Santner, SJ; Smith, IE, 1985) |
| "Fifty-seven patients with actively progressing advanced breast cancer have been assessed for their response to low-dose aminoglutethimide (125 mg bd) without steroid replacement." | 7.67 | Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. ( Murray, R; Pitt, P, 1985) |
| "45 women (postmenopausal or after former oophorectomy) with metastatic breast cancer resistant to tamoxifen as well as to chemo- and radiotherapy were treated with aminoglutethimide (750 mg or 1000 mg resp." | 7.67 | [Aminoglutethimide therapy in advanced breast cancer]. ( Kühböck, J; Ludwig, H; Pötzi, P; Zielinski, C, 1985) |
| "Forty-five women with far-advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG), 1000 mg p." | 7.66 | Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1982) |
| "Sixty-five patients with advanced breast cancer, progressive despite prior endocrine therapy in all cases and prior chemotherapy in most cases, were treated with aminoglutethimide, 250 mg four times a day." | 7.66 | Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. ( Coates, AS; Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1982) |
| "Thirty-four postmenopausal patients with advanced breast cancer had an overall objective response rate of 47% when treated with aminoglutethimide and hydrocortisone initially and a response rate of 24% when crossed over to therapy with tamoxifen after progression on aminoglutethimide." | 7.66 | Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. ( Boucher, AE; Dixon, RJ; Harvey, HA; Lipton, A; Santen, RJ; Shafik, AS; White, DS, 1982) |
| "Thirty-eight metastatic breast cancer patients were treated with aminoglutethimide." | 7.66 | Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. ( Blumenschein, GR; Buzdar, AU; Legha, SS; Powell, KC, 1982) |
| "Aminoglutethimide in combination with hydrocortisone provides an effective therapy in postmenopausal advanced breast cancer patients, with response rates of 37." | 7.66 | Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; McKinna, JA; Morgan, M; Smith, IE, 1982) |
| "We describe sequential response to aminoglutethimide after eventual failure of treatment with tamoxifen in a patient with metastatic breast cancer." | 7.66 | Response to aminoglutethimide after tamoxifen therapy in advanced breast cancer. ( Allison, RW; Furnival, CM; Lee, JF; Roberts, SJ, 1982) |
| "Sixty-five patients with actively progressing advanced breast cancer were treated with aminoglutethimide, a drug which inhibits adrenal steroid synthesis and decreases peripheral conversion of androgens to oestrogens." | 7.66 | Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. ( Jerums, G; Murray, RM; Pitt, P, 1981) |
| "Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone." | 7.66 | Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Powles, TJ; Smith, IE; White, H, 1983) |
| "Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy." | 7.66 | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1983) |
| "During the last 2 years we have treated 24 patients (23 females and 1 male) with aminoglutethimide plus glucocorticoid for advanced breast cancer." | 7.66 | Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach. ( Dahl, O; Kvinnsland, S, 1983) |
| "Oestrogen receptor (ER) measurements in metastatic and primary tumours from patients with breast cancer have been correlated with the objective tumour response to treatment with aminoglutethimide (24 patients) or tamoxifen (39 patients)." | 7.66 | Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen. ( Holdaway, IM, 1981) |
| "Aminoglutethimide in combination with dexamethasone has been used in 44 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptors." | 7.66 | Aminoglutethimide in the treatment of metastatic breast cancer. ( Troner, MB, 1982) |
| "A group of 213 unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide, 250 mg 4 times a day, and hydrocortisone, 20 mg 2 times a day." | 7.66 | Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. ( Harris, AL; Powles, TJ; Smith, IE, 1982) |
| "Aminoglutethimide was applied for treatment of 10 patients (8 postmenopausal, 2 ovariectomized) with metastasizing breast cancer." | 7.66 | [Treatment of metastasizing breast cancer with aminoglutethimide]. ( Aiginger, P; Kübböck, J; Linkesch, W; Ludwig, H; Pötzi, P, 1982) |
| "Seventy-three women with metastatic breast cancer were treated with aminoglutethimide and dexamethasone." | 7.66 | Treatment of metastatic breast cancer with aminoglutethimide. ( Asbury, RF; Bakemeier, RF; Bennett, JM; Fölsch, E; McCune, CS; Savlov, E, 1981) |
| "Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women." | 7.66 | Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. ( Cox, CE; Harvey, HA; Lawrence, BV; Lipton, A; Santen, RJ; Smart, EK; Wells, SA; White, DS, 1980) |
| "Aminoglutethimide (AG) with Dexamethasone has been utilized in 26 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptor." | 7.66 | Aminoglutethimide in the management of metastatic breast cancer. ( Savaraj, N; Troner, MB, 1980) |
| "Aminoglutethimide treatment caused significant alterations in the metabolite profiles of estradiol and estrone but with large interindividual variations." | 6.66 | Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide. ( Lønning, PE; Skulstad, P, 1989) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 6.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer." | 6.16 | Tamoxifen therapy of metastatic breast cancer. ( Manni, A, 1987) |
| "3-fold) than that of R-AG and appears to be most likely the cause for the other pharmacokinetic differences observed." | 5.30 | Pharmacokinetics of S- and R-enantiomers of aminoglutethimide following oral administration of racemic drug in breast cancer patients. ( Abd el-Warith, A; Alshowaier, IA; el-Yazigi, A; Ezzat, A; Nicholls, PJ, 1999) |
| "Hormonal therapy of breast cancer is the oldest treatment in advanced disease." | 5.29 | Megestrol acetate in advanced breast carcinoma. ( Espie, M, 1994) |
| "As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer." | 5.28 | [The use of aminoglutethimide in the treatment of metastatic breast cancer]. ( Bellora, MG; Bergamino, T; Ciancio, A; Ferrero, A; Sismondi, P; Zola, P, 1991) |
| "A total of 34 patients with advanced breast cancer entered the study: 17 were given 1,000 mg/day and 17 received 500 mg/day for at least 3 months." | 5.28 | Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses. ( Ambroso, G; Balli, M; Bonciarelli, G; Camaggi, CM; Cellerino, R; Indelli, M; Malacarne, P; Martoni, A; Miseria, S; Strocchi, E, 1991) |
| " This dosage regimen appears of comparable efficacy to previously reported higher dosage regimens with reduced toxicity compared to low dose regimens without hydrocortisone." | 5.28 | Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. ( Cantwell, BM; Carmichael, J; Dawes, P; Farndon, J; Harris, AL; Robinson, A; Wilson, R, 1989) |
| "Antipyrine was given as a single test dose before and after 3 mo of AG treatment, whereas theophylline and digitoxin kinetics were investigated at steady state in patients receiving these drugs therapeutically before and after AG therapy." | 5.27 | Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer. ( Bakke, OM; Kvinnsland, S; Lønning, E, 1984) |
| "Aminoglutethimide (Ag) has been used in different dosages with and without combined treatment with glucocorticoids for the suppression of peripheral plasma levels of steroidal hormones." | 5.27 | Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer. ( Alexieva-Figusch, J; de Jong, FH; Klign, JG; Lamberts, WJ; van Gilse, HA, 1987) |
| "A total of 79 patients with metastatic breast cancer entered the study, and their plasma and urine samples were analyzed by high-performance liquid chromatography (HPLC)." | 5.27 | Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ( Höffken, K; Miller, AA; Miller, BE; Schmidt, CG, 1987) |
| "A 54-year-old woman had a primary breast cancer with an estrogen receptor of 11." | 5.27 | Response to aminoglutethimide after failure of tamoxifen therapy in breast cancer. ( Carter, RD; Muchmore, JH; Sutherland, CM, 1985) |
| "Its role in the biology of breast cancer is unclear." | 5.26 | Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ( Bird, CE; Clark, AF; Masters, V; Sterns, EE, 1982) |
| "In the therapy of metastatic breast cancer with high dose MAP the cortisol like effect could be shown even in long term treatment." | 5.26 | [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer]. ( Blossey, HC; Kleeberg, U; Köbberling, J; Nagel, GA; Wander, HE, 1982) |
| "Human breast neoplasms can be divided into hormone-dependent and hormone-independent subtypes." | 5.26 | Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. ( Boucher, AE; Harvey, H; Lipton, A; Samojlik, E; Santen, RJ; Worgul, TJ, 1982) |
| "Aminoglutethimide is an inhibitor of various steroid hydroxylation reactions in the adrenal gland, the ovary, the testis and the placenta; furthermore, the extraglandular estrogen synthesis is inhibited by blocking the aromatase in the subcutaneous fatty tissue." | 5.26 | [Aminoglutethimide - a new drug for the after care in breast cancer]. ( Rabe, D; Rabe, T; Runnebaum, B, 1981) |
| "Aminoglutethimide is an investigational agent of proven benefit in the treatment of metastatic breast carcinoma." | 5.26 | Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. ( Hamilton, R; Harvey, HA; Lawrence, B; Lipton, A; Mercurio, T; Santen, RJ, 1978) |
| "ABCSG-06 investigated the efficacy of tamoxifen vs tamoxifen plus aminoglutethimide in postmenopausal women with hormone receptor-positive breast cancer." | 5.17 | Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. ( Balic, M; Dubsky, P; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kwasny, W; Mlineritsch, B; Moik, M; Pfeiler, G; Ploner, F; Renner, K; Samonigg, H; Sandbichler, P; Seifert, M; Selim, U; Singer, C; Steger, GG; Stöger, H, 2013) |
| "The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifen-based therapy." | 5.13 | Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. ( Dietze, O; Filipits, M; Gnant, MF; Greil, R; Grill, R; Huynh, A; Jakesz, R; Kwasny, W; Lax, S; Lehnert, M; Rudas, M; Schippinger, W; Singer, C; Stierer, M; Stiglbauer, W, 2008) |
| "3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0." | 5.12 | Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. ( Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C, 2007) |
| "To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer." | 5.10 | Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Schmid, M; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Taucher, S; Tausch, C; Wette, V, 2003) |
| "The study compares letrozole (Femara and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with anti-estrogens." | 5.09 | [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, Kh; Friedrich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, NO; Reichard, P; Romieu, G, 1999) |
| "The efficacy of combined endocrine therapy with tamoxifen (TAM), aminoglutethimide (AG), and hydrocortisone (H) or tamoxifen and fluoxymesterone (FLU) was evaluated against treatment with tamoxifen alone in 311 patients above 65 years of age with a first recurrence of a metastatic breast cancer." | 5.09 | Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. ( Andersen, J; Andersson, M; Bastholt, L; Christensen, IJ; Dombernowsky, P; Kamby, C; Mouridsen, HT; Munkholm, P; Møller, KA; Rose, C, 2000) |
| "Three hundred eighty postmenopausal breast cancer patients receiving adjuvant tamoxifen treatment for 3 years were randomized to either continue tamoxifen for 2 more years or to switch to low-dose aminoglutethimide (250 mg daily) for 2 years." | 5.09 | Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. ( Amoroso, D; Boccardo, F; Caroti, C; Cruciani, G; Farris, A; Mesiti, M; Mustacchi, G; Romeo, D; Rubagotti, A; Schieppati, G; Villa, E, 2001) |
| "One hundred and twelve post menopausal or post oophorectomy women with advanced breast cancer (BC) who had all previously had aminoglutethimide (AG) were treated with the potent aromatase inhibitor 4-hydroxy androstenedione (4-OHA)." | 5.08 | Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. ( Murray, R; Pitt, P, 1995) |
| "Trilostane and aminoglutethimide, both given with a physiological replacement dose of hydrocortisone, were randomly allocated to 112 eligible patients with postmenopausal advanced breast cancer." | 5.08 | Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. ( Bachelot, F; Barley, VL; Blackledge, GR; Dermaille, A; Fargeot, P; Namer, M; Pouillart, J; Rowland, CG; Tyrrell, CJ; Williams, CJ, 1995) |
| "A third series of randomized tests was undertaken to evaluate the efficacy of postoperative adjuvant hormone therapy (tamoxifen, diethylstilbestrol, orimethen amino glutethymide) in breast cancer patients." | 5.08 | [Effectiveness of adjuvant hormone therapy in breast cancer]. ( Bozhok, AA; Ivanov, VG; Ivanova, OA; Moiseenko, VM; Semiglazov, VF; Tsyrlina, EV, 1996) |
| "We studied the clinical and endocrine effects of the aromatase inhibitor formestane (4-hydroxyandrostenedione, 4-OHA) in heavily pretreated breast cancer patients (median number of previous endocrine treatments 2, range 1-4)." | 5.08 | Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. ( Anker, G; Geisler, J; Johannessen, DC; Lønning, PE, 1996) |
| "A third series of randomized evaluation of postoperative (adjuvant) hormone therapy (tamoxifen, sinestrol and orimeten) was carried out in breast cancer patients." | 5.08 | [Postoperative hormone therapy of breast cancer (analysis of overall survival)]. ( Barash, NI; Bozhok, AA; Ivanov, VG; Ivanova, OA; Migmanova, NS; Moiseenko, VM; Popova, RT; Seleznev, IK; Semiglazov, VF; Tsyrlina, EV, 1996) |
| "A phase III randomized trial was performed to determine whether combination hormonal therapy with aminoglutethimide (AG) and hydrocortisone (HC) plus megestrol acetate (MA) improved response rates, response duration, or increased survival over the sequential use of each hormone in women with estrogen receptor-positive metastatic breast cancer (MBC) who had maintained stable disease for at least 6 months or responded to tamoxifen." | 5.08 | Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. ( Budd, GT; Congdon, JE; Green, SJ; Hynes, HE; Martino, S; O'Sullivan, J; Osborne, CK; Russell, CA, 1997) |
| "In a European multicentre phase II study, 80 postmenopausal patients (pts) with advanced breast cancer progressing on aminoglutethimide (AG) at daily doses of > or = 500 mg were enrolled." | 5.08 | Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. ( Bonneterre, J; di Salle, E; Lanzalone, S; Murray, R; Paridaens, R; Piscitelli, G; Roché, H; Serin, D; Thürlimann, B; Zurlo, MG, 1997) |
| "The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens." | 5.08 | Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G, 1998) |
| "In order to evaluate the effectiveness of second and third line hormone therapy for postmenopausal (spontaneous or surgical) women with metastatic tamoxifen-resistant breast cancer, 293 women aged 36 to 91 (mean 63." | 5.07 | [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]. ( Ayme, Y; Carton, M; Daban, A; Delozier, T; Fargeot, P; Ferri, L; Fumoleau, P; Garcia-Giralt, E; Gorins, A; Omodei Zorini, C, 1994) |
| "Aminoglutethimide (Ag) is a potent aromatase-enzyme inhibitor used in the treatment of patients with breast cancer." | 5.07 | Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer. ( Carella, MJ; Dimitrov, NV; Gossain, VV; Rovner, DR; Srivastava, L, 1994) |
| "Trilostane and Aminoglutethimide, each given with a physiological replacement dose of hydrocortisone, were randomly allocated to 72 eligible postmenopausal advanced breast cancer patients; following treatment failure on either drug the patient continued with the other drug, if in a suitable clinical condition." | 5.07 | Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. ( Barley, VL; Blackledge, GR; Rowland, CG; Tyrrell, CJ; Williams, CJ, 1993) |
| "Tamoxifen and aminoglutethimide are two hormone therapies reported to be effective palliative approaches for patients with metastatic breast cancer." | 5.07 | Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. ( Andersen, JW; Cummings, FJ; Davis, TE; Gale, KE; Horton, J; Mansour, EG; Smith, TJ; Tormey, DC; Wolter, JM, 1994) |
| "In a randomized trial of second line hormone therapy 56 postmenopausal women with advanced breast cancer received low dose aminoglutethimide (AGT) 125 mg twice daily without hydrocortisone (27 patients), or hydrocortisone (HC) 20 mg twice daily (29 patients)." | 5.07 | Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. ( Bates, T; Coltart, RS; Ebbs, SR; Fraser, SC; Mercer, PM, 1993) |
| "The study purpose was to evaluate aminoglutethimide (AG) as adjuvant therapy in patients with primary node-positive breast cancer in a randomized double-blind placebo-controlled trial." | 5.07 | Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. ( Coombes, RC; Easton, D; Ford, HT; Jones, AL; Law, M; McKinna, JA; Nash, A; Powles, TJ; Smith, IE; Tidy, A, 1992) |
| "The clinical and biochemical effects of combined treatment with the two aromatase inhibitors aminoglutethimide and 4-hydroxyandrostenedione were evaluated in 10 patients suffering from advanced breast cancer." | 5.07 | Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. ( Dowsett, M; Ekse, D; Jacobs, S; Johannessen, DC; Jones, A; Lønning, PE; McNeil, F; Powles, TJ, 1992) |
| "A randomized study comparing low-dose aminoglutethimide (AG) with and without hydrocortisone (HC) was performed to investigate whether corticosteroid replacement contributes to the therapeutic effects of the drug administered as a front-line endocrine therapy in postmenopausal advanced breast cancer." | 5.07 | Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. ( Bacchi, M; Bisagni, G; Boni, C; Brugia, M; Carpi, A; Ceci, G; Cocconi, G; Di Costanzo, F; Franciosi, V; Gori, S, 1992) |
| "One hundred and twenty patients with metastatic breast cancer, whose disease progressed on hormonal therapy with tamoxifen, were treated with aminoglutethimide." | 5.06 | Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. ( Biran, S; Brufman, G, 1990) |
| "In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared." | 5.06 | Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989) |
| "One hundred and one postmenopausal patients with advanced breast cancer were enrolled in a randomized phase II clinical trial to investigate the clinical and hormonal response to aminoglutethimide administered at daily doses of 2 x 125 mg, 3 x 125 mg or 2 x 250 mg, with no addition of hydrocortisone." | 5.06 | Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Bonfrer, JM; Bruning, PF; de Jong-Bakker, M; Hart, AA; Moolenaar, AJ; Nooijen, WJ; van der Linden, E, 1989) |
| "One hundred-twenty-seven advanced breast cancer patients who had been -for most of them- heavily pretreated with chemo- and/or hormone therapy received 500 mg aminoglutethimide and 30 mg hydrocortisone/day." | 5.06 | [Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast]. ( Bonneterre, J; Demaille, A; Pion, JM, 1987) |
| "The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer." | 5.06 | Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986) |
| "Three hundred and twenty-two postmenopausal patients with primary breast cancer and ipsilateral axillary node involvement were randomized to receive aminoglutethimide and hydrocortisone or placebo for 2 years in a double blind randomized trial between April 1980 and March 1985." | 5.06 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. ( Bradbeer, J; Chilvers, C; Coombes, RC; Easton, D; Ford, HT; McKinna, A; Powles, TJ; Smith, IE; White, H; Yarnold, J, 1987) |
| "Fifty postmenopausal women with advanced breast cancer were included in the following randomized phase II trial: 25 patients received aminoglutethimide 1000 mg and hydrocortisone 40 mg daily." | 5.06 | A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer. ( Gennatas, CS; Kalovidouris, A; Kouvaris, J; Papavasiliou, C; Paraskevas, GA; Trichopoulos, D, 1987) |
| "222 patients with disseminated breast cancer have been randomised to receive either a combination of hormone therapies using tamoxifen, aminoglutethimide with hydrocortisone, and danazol (TAD), or tamoxifen alone." | 5.05 | Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. ( Ashley, S; Coombes, RC; Ford, HT; Gazet, JC; Nash, AG; Neville, AM; Powles, TJ, 1984) |
| "A group of 122 postmenopausal patients with histologically proven node-positive primary breast cancer have been randomized to receive aminoglutethimide-hydrocortisone or placebo aminoglutethimide-placebo hydrocortisone for 2 years." | 5.05 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. ( Bettelheim, R; Chilvers, C; Coombes, RC; Dowsett, M; Ford, HT; Gazet, JC; Gordon, C; Powles, TJ; Smith, IE; Zava, D, 1982) |
| "The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid." | 5.05 | Aminoglutethimide dose and hormone suppression in advanced breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983) |
| "The endocrine effects of replacement doses of hydrocortisone in postmenopausal women with advanced breast cancer were compared with the same doses of hydrocortisone plus aminoglutethimide." | 5.05 | Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1984) |
| "Aminoglutethimide (AG) has antitumor activity in disseminated breast cancer similar to that of surgical adrenalectomy." | 5.05 | The role of aromatase inhibitors in breast cancer. ( Powles, TJ, 1983) |
| "Altogether 117 patients with advanced breast cancer were treated with either tamoxifen 10 mg by mouth twice daily or aminoglutethimide 250 mg by mouth four times daily with hydrocortisone 20 mg twice daily in a randomised cross-over trial in which patients who failed to respond to the first treatment or relapsed while receiving it were switched to the other." | 5.05 | Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. ( Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Smith, IE; Villardo, A; Walsh, G; White, H, 1981) |
| "Aminoglutethimide inhibited adrenal steroid synthesis, as assessed by serial estimations of plasma dehydroepiandrosterone sulphate in ten patients with advanced breast cancer." | 5.05 | Aminoglutethimide therapy in advanced breast cancer. ( Anderson, JL; Black, RB; Phillipou, G, 1981) |
| "Thirty-eight patients with advanced breast cancer, resistant to prior endocrine therapy and in most cases prior chemotherapy, were treated with aminoglutethimide, 250 mg qds." | 5.05 | The treatment of metastatic breast cancer with aminoglutethimide. ( Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1981) |
| "Tamoxifen (TAM), a standard endocrine treatment for advanced breast cancer, probably acts by competing for the estrogen receptor protein in the breast tumor cells." | 5.05 | Tamoxifen and aminoglutethimide in advanced breast cancer. ( Ascoli, DM; Corkery, J; Gelman, RS; Henderson, IC; Hourihan, J; Leonard, RC; Salhanick, HA, 1982) |
| "In a control randomized cross-over trial, 117 patients with advanced breast cancer were treated initially either with tamoxifen (10 mg p." | 5.05 | Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. ( Gazet, JC; Harris, AL; McKinna, JA; Morgan, M; Smith, IE, 1982) |
| "Sixty-six post-menopausal women with metastatic breast cancer were randomised to receive tamoxifen or tamoxifen with aminoglutethimide." | 5.05 | A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer. ( Calman, K; Campbell-Ferguson, J; Habeshaw, T; Kaye, S; Macbeth, F; Milsted, R; Sangster, G; Smith, D, 1985) |
| "Aminoglutethimide, a drug known to block adrenal steroidogenesis and peripheral aromatization of androgens to estrogens, has been found effective in the treatment of breast cancer." | 5.05 | Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer. ( Ardizzoni, A; Conte, P; Lionetto, R; Pronzato, P; Rosso, R, 1985) |
| "The response rate of advanced postmenopausal breast cancer patients to treatment with aminoglutethimide (AG) + danazol was significantly worse than that with AG alone." | 5.05 | Antagonism of aminoglutethimide and danazol in the suppression of serum free oestradiol in breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Murray, RM; Pitt, P, 1985) |
| "Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy." | 4.82 | A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003) |
| "The new generation of selective aromatase inhibitors (anastrozole, letrozole and exemestane) offer a significant efficacy and safety advantage over both older agents in this class (aminoglutethimide) and the progestins (megestrol acetate (MA)), as second-line treatment for postmenopausal women with advanced hormone-dependent breast cancer who have failed on tamoxifen therapy." | 4.81 | A summary of second-line randomized studies of aromatase inhibitors. ( Buzdar, AU, 2001) |
| "5 mg/d) against megestrol acetate and aminoglutethimide, respectively, in patients with locally advanced or metastatic breast cancer." | 4.80 | Pivotal trials of letrozole: a new aromatase inhibitor. ( Smith, IE, 1998) |
| "Aromatase inhibitors used in breast cancer, are drugs that inhibit the transformation of androstenedione and testosterone, respectively in estradiol and estrone." | 4.80 | [Aromatase inhibitors]. ( Bonneterre, J; Feutrie, ML, 1999) |
| "Hormonotherapy in metastatic breast cancer is actually performed using 3 therapeutic classes: antiestrogen as tamoxifen (TAM), progestins, megestrol acetate (MA) and medroxyprogesterone acetate (MPA), aromatase-inhibitors as aminoglutethimide (AG)." | 4.79 | [Progestational agents and bone metastasis in breast cancer]. ( Bonneterre, J; Leriche, N, 1997) |
| " Among the steroid substrate analogs, 4-hydroxyandrostenedione has been shown to be effective in breast cancer patients with advanced disease and was recently approved for treatment in the United Kingdom." | 4.78 | Aromatase, its inhibitors and their use in breast cancer treatment. ( Brodie, AM, 1993) |
| "Aminoglutethimide was the first aromatase inhibitor to be used in breast cancer therapy but, since it interacts with the synthetic glucocorticoids, hydrocortisone must also be given as a replacement." | 4.78 | Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer. ( Borja, J; Pérez, N, 1992) |
| "In postmenopausal women with breast cancer, aromatase, which is the enzyme converting androstenedione to estrone and testosterone to estradiol, is the rate-limiting step in estrogen biosynthesis." | 4.78 | Recent progress in development of aromatase inhibitors. ( Santen, RJ, 1990) |
| "During the last decade aminoglutethimide has been recognised as a valuable alternative in endocrine therapy for advanced breast cancer." | 4.77 | Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. ( Kvinnsland, S; Lønning, PE, 1988) |
| "Aminoglutethimide is an effective treatment for advanced postmenopausal breast cancer, acting in a novel way." | 4.77 | Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review. ( Harris, AL, 1985) |
| "We evaluated the comparative effects of aminoglutethimide (AG) on androgen and estrogen levels estrone ([E1], estradiol [E2], plasma dehydroepiandrosterone-sulfate [DHEA-S], testosterone [T], dihydrotestosterone [DHT], delta 4-androstenedione [delta 4-A]), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin in postmenopausal patients with breast cancer randomly allocated to either AG treatment or bilateral surgical adrenalectomy as a control group." | 4.76 | Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. ( Samojlik, E; Santen, RJ; Veldhuis, JD; Wells, SA, 1980) |
| "Approximately one third of human breast carcinomas are hormone dependent and regress upon reduction of circulating estrogen levels." | 3.76 | Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors. ( Brodie, AM; Santen, RJ, 1986) |
| "The results of treatment of 959 breast cancer patients by AG and glucocorticoids in several studies are reviewed." | 3.75 | [Chemical adrenalectomy induced by aminoglutethimide in the treatment of breast cancer. A review]. ( Cikes, M, 1983) |
| " The aim of this paper was to study if a melatonin pretreatment prior to aminoglutethimide increases the efficiency of the aromatase inhibitor used in treating breast cancer." | 3.73 | Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. ( Alonso-González, C; Cos, S; González, A; Martínez-Campa, C; Mediavilla, MD; Sánchez-Barceló, EJ, 2005) |
| " Oophorectomies with either aminoglutethimide therapy or adrenalectomy were effective remedies for breast cancer progression due to high DHEA-S." | 3.71 | High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. ( Fletcher, WS; Morris, KT; Pommier, RF; Schmidt, J; Toth-Fejel, S, 2001) |
| " Treatment with the aromatase inhibitor aminoglutethimide increases the concentration of gamma-glutamyl transpeptidase (gamma-GT) in breast cancer patients." | 3.70 | Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients. ( Berge, R; Berntsen, H; Ekse, D; Johannessen, DC; Lønning, PE; Netteland, B; Svardal, A, 1998) |
| "In this study, we evaluated the effect of estrogen suppression with three aromatase inhibitors, aminoglutethimide (n = 30), formestane (n = 12), and exemestane (n = 10), and the progestin megestrol acetate (n = 21) on plasma total homocysteine (tHcy) in patients suffering from advanced breast cancer." | 3.70 | Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. ( Anker, GB; Johannessen, DC; Lien, EA; Lonning, PE; Refsum, H; Ueland, PM, 1999) |
| "54 patients (pts) with metastatic breast cancer were treated with aminoglutethimide 250 mg p." | 3.69 | [Use of aminoglutethimide in the hormonal treatment of patients with advanced breast cancer]. ( Czech, I; Dziewulska-Bokiniec, A; Wojtacki, J, 1994) |
| "A major obstacle to the understanding of the mechanisms of action of aromatase inhibitors in breast cancer is the observation that plasma estrogens are sustained at about 30-50% of their control levels despite 85-95% inhibition of the conversion of tracer androstenedione (A) to estrone (E1)." | 3.69 | A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. ( Ekse, D; Lønning, PE, 1995) |
| "The effects of treatment with the aromatase inhibitors aminoglutethimide (AG) and formestane or the synthetic progestin megestrol acetate (MA) on plasma levels of insulin-like growth factor I (IGF-1), IGF-II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status were investigated in 39 patients suffering from advanced breast cancer." | 3.69 | Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. ( Frost, VJ; Helle, SI; Holly, JM; Lønning, PE; van der Stappen, JW, 1996) |
| "Twenty-eight and 24 patients with advanced breast cancer were treated with Aminoglutethimide (AG) or AG + Tamoxifen (AG + TAM) from June 1984 to June 1989, respectively." | 3.68 | [Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer]. ( Hisamatsu, K; Nomura, Y; Tashiro, H, 1992) |
| "The influence of the prototype aromatase inhibitor Aminoglutethimide (AG) and its analogue Rogletimide (RG) on peripheral aromatisation were investigated in 13 postmenopausal women with advanced breast cancer." | 3.68 | The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. ( Dowsett, M; Jacobs, S; Jones, AL; Lønning, PE; MacNeill, FA; Powles, TJ, 1992) |
| "Plasma insulin-like growth factor-I (IGF-I) was measured in breast cancer patients before and during treatment with tamoxifen, goserelin or aminoglutethimide." | 3.68 | Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. ( Aakvaag, A; Johannessen, DC; Lien, EA; Lønning, PE, 1992) |
| "Eleven postmenopausal patients with advanced breast cancer were assessed for their response and endocrine changes to low-dose aminoglutethimide (250 mg twice a day) therapy without steroid administration." | 3.68 | Low-dose aminoglutethimide therapy without glucocorticoid administration. Clinical and hormonal findings. ( Kahán, Z; Tóth, I; Vecsernyés, M, 1992) |
| "Aminoglutethimide is effective in the treatment of breast cancer in postmenopausal patients as a result of its inhibition of aromatase." | 3.68 | Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. ( Cantwell, BM; Dowsett, M; Harris, AL; Mehta, A, 1991) |
| "44 postmenopausal women with progressive soft tissue, osseous and/or pleuropulmonal metastases of breast cancer were treated with aminoglutethimide (Rodazol) and hydrocortisone." | 3.68 | [Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer]. ( Brockmann, B; Geschke, E; Schmidt, UM, 1991) |
| "Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND)." | 3.68 | Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. ( Ashley, SE; Coombes, RC; Ellin, CL; Hardy, JR; Judson, IR; Powles, TJ; Sinnett, HD, 1990) |
| "To confirm that concomitant administration of aminoglutethimide (AG) reduces plasma levels of medroxyprogesterone acetate (MPA), MPA levels were assayed in six patients with advanced breast cancer receiving the two agents." | 3.68 | Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate. ( Bye, A; Cranny, A; Daly, PA; Feely, J; Halpenny, O, 1990) |
| "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer." | 3.68 | Radiotherapy enhances the toxicity of aminoglutethimide. ( Buzdar, AU; Hortobagyi, GN; Vanek, N, 1990) |
| "59 women with metastatic breast cancer in menopause were treated with 1 g/day aminoglutethimide and 3 mg/d dexamethasone." | 3.68 | [Experiences with Rodazol therapy in the treatment of postmenopausal patients with metastatic breast cancer]. ( Gürtler, R; Müller, U; Schmidt, UM; Stier, G; Tanneberger, S, 1990) |
| " It was completely suppressed in one out of two breast cancer patients receiving orimeten (aminoglutethimide)." | 3.68 | [Aromatase activity in lymphocytes of cancer patients and healthy subjects]. ( Bershteĭn, LM; Dil'man, VM; Kondrat'ev, VB, 1990) |
| "Aminoglutethimide is an aromatase inhibitor that is successfully used for endocrine treatment of advanced breast cancer." | 3.68 | Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. ( Lønning, PE, 1990) |
| "The clinical and endocrine effects of low-dose aminoglutethimide without hydrocortisone in patients with advanced breast cancer were investigated." | 3.67 | Low-dose aminoglutethimide in treatment of advanced breast cancer. ( Bozek, T; Carr, L; Dowsett, M; Gazet, JC; Jeffcoate, SL; Kurkure, A; McKinna, JA; Smith, IE; Stuart-Harris, R, 1984) |
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 3.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 3.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "Aminoglutethimide inhibits the synthesis of oestrogens in adrenal and non-adrenal tissues and can be successfully used in the treatment of advanced breast cancer." | 3.67 | [Panmyelopathy induced by aminoglutethimide. Report of a clinical case]. ( Wander, HE, 1984) |
| "A patient with advanced breast cancer who died of septicemia associated with aminoglutethimide induced agranulocytosis, is reported." | 3.67 | Aminoglutethimide-induced bone marrow injury. Report of a case and review of the literature. ( Keller, AM; Newcomer, LN; Young, JA, 1984) |
| "Thirty-one postmenopausal patients with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1 000 - 1 250 mg/d) plus hydrocortisone replacement." | 3.67 | Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment. ( Bezwoda, WR; Browde, S; Derman, DP; Goss, G; Lange, M, 1984) |
| "A 67-year-old patient with breast carcinoma on treatment with aminoglutethimide (AG) developed profound leukopenia and sepsis." | 3.67 | Aminoglutethimide-induced leukopenia: a case report and review of the literature. ( Gez, E; Sulkes, A, 1984) |
| "In a phase II clinical trial, 38 postmenopausal women with advanced breast cancer were treated with aminoglutethimide and replacement hydrocortisone." | 3.67 | Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer. ( Bonfrèr, JG; Bruning, PF; de Jong-Bakker, M; Engelsman, E; Hamersma-vd Linden, E; Nooyen, W, 1984) |
| "Aminoglutethimide (AG) was administered as palliative therapy in 112 patients with metastatic breast cancer." | 3.67 | Aminoglutethimide in patients with metastatic breast cancer. ( Dao, TL; Nemoto, T; Patel, JK; Rosner, D, 1989) |
| "Plasma level, plasma clearance, production rate and interconversions of oestrone and oestrone sulphate were measured in six breast cancer patients receiving aminoglutethimide therapy." | 3.67 | Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. ( Johannessen, DC; Lønning, PE; Thorsen, T, 1989) |
| "In an attempt to define the activity and toxicity of low-dose aminoglutethimide plus steroid replacement in advanced breast cancer, we treated 40 patients with aminoglutethimide 500 mg/day + hydrocortisone 50 mg/day." | 3.67 | Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies. ( Ambroso, G; Crivellari, D; Frustaci, S; Galligioni, E; Gasparini, G; Lo Re, G; Monfardini, S; Talamini, R; Vaccher, E, 1989) |
| "Plasma levels of estrone and estrone sulfate were measured in 16 postmenopausal women with advanced breast cancer before and during chronic aminoglutethimide therapy." | 3.67 | Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. ( Ekse, D; Johannessen, DC; Lønning, PE; Thorsen, T, 1989) |
| "From July 1980 to June 1983, 61 postmenopausal women with progressive metastatic breast cancer were treated with aminoglutethimide, 250 mg 4 times daily, plus cortisone acetate, 25 mg twice daily." | 3.67 | Aminoglutethimide in advanced breast cancer. ( Bella, M; Bisagni, G; Ceci, G; Cocconi, G; Passalacqua, R, 1985) |
| "The endocrine effects of aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily were assessed in 45 postmenopausal women with advanced breast cancer." | 3.67 | Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen. ( Cantwell, BM; Dowsett, M; Farndon, J; Harris, AL; Needham, G; Sainsbury, JR; Wilson, R, 1986) |
| "One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)." | 3.67 | Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986) |
| "We analyzed the results of clinical studies on the therapeutic efficacy of hormone monotherapy with tamoxifen, medroxyprogesterone acetate, and aminoglutethimide in metastatic breast cancer, which were published between 1971 and 1986 and involved altogether 7000 patients." | 3.67 | On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. ( Petru, E; Schmähl, D, 1987) |
| "5 mg, twice a day) aminoglutethimide (AG), without hydrocortisone (HC), escalating at monthly intervals to a conventional dose of AG (500 mg twice a day) combined with HC, were studied in 33 postmenopausal breast cancer patients." | 3.67 | Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. ( D'Souza, A; Donaldson, A; Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE; Stuart-Harris, R, 1985) |
| "Sixty patients suffering from metastatic breast cancer, whose disease progressed on chemotherapy and/or hormonal therapy with tamoxifen, were treated with aminoglutethimide." | 3.67 | Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen. ( Biran, S; Brufman, G, 1985) |
| "Seventy-two women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone (AG)." | 3.67 | Aminoglutethimide as second line therapy in advanced breast cancer. ( Blomqvist, C; Elomaa, I; Rissanen, P, 1986) |
| "We treated 21 patients with advanced breast cancer with buserelin, aminoglutethimide and cortisone acetate in an attempt to obtain a complete estrogen blockade both in premenopausal and postmenopausal patients." | 3.67 | Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations. ( Ferrari, V; Marini, G; Marpicati, E; Montini, E; Moretti, R; Simoncini, E; Zaniboni, A, 1988) |
| "Postmenopausal patients with metastatic breast cancer were treated with aminoglutethimide (AG) and high-dose medroxyprogesterone acetate (MPA)." | 3.67 | Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. ( Blijham, GH; Mellink, WA; Meulenberg, PM; Van Deijk, WA, 1985) |
| "Plasma lipids, apolipoproteins, and gamma-glutamyl-transpeptidase (GGT) were measured in 28 patients receiving aminoglutethimide (500 mg) and hydrocortisone (30 or 40 mg) for advanced breast cancer." | 3.67 | Variations in lipoproteins during aminoglutethimide therapy. ( Bonneterre, J; Demaille, A; Demarquilly, C; Fruchart, JC; Ghalim, N; Nguyen, M; Puchois, P, 1987) |
| "In this small study, the effect of aminoglutethimide on the disposition of oestrogens in women with advanced breast cancer was investigated using bolus injections of 4-[14C]-oestradiol and 6,7-[3H]-oestrone sulphate, alone or in combination." | 3.67 | Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. ( Kvinnsland, S; Lønning, PE; Thorsen, T; Ueland, PM, 1987) |
| "This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer." | 3.67 | Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987) |
| "Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%." | 3.67 | [The use of aminoglutethimide (orimeten) in disseminated breast cancer]. ( Bassalyk, LS; Garin, AM; Lichinitser, MR; Nadezhdina, TM; Vyshinskaia, GV, 1987) |
| "Seventy-nine postmenopausal patients received aminoglutethimide (AG; 750 mg daily) and hydrocortisone therapy for metastatic or locally recurrent breast cancer following the failure of other hormonal therapy." | 3.67 | Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity. ( Gilmore, OJ; Plowman, PN; Rowell, NP, 1987) |
| "In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%)." | 3.67 | Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status. ( Bezwoda, WR; Browde, S; Dansey, RD; Hesdorffer, CS, 1987) |
| "Aminoglutethimide (AG) is now an established agent for producing a 'medical adrenalectomy' in patients with breast cancer." | 3.67 | Aminoglutethimide therapy in breast cancer: relationship of blood levels to drug-related side effects. ( Boucher, AE; Demers, LM; Santen, RJ, 1987) |
| "Eighty-seven consecutive patients with metastatic breast cancer were treated with aminoglutethimide plus hydrocortisone." | 3.67 | Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments. ( Bonadonna, G; Brambilla, C; Tancini, G; Zambetti, M, 1987) |
| "The pharmacokinetics of the optical enantiomers of warfarin (R-warfarin and S-warfarin) were investigated in patients treated for breast cancer with aminoglutethimide (AG)." | 3.67 | The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer. ( Kvinnsland, S; Lønning, PE; Ueland, PM, 1986) |
| "Aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily was used to treat 76 postmenopausal women with advanced breast cancer." | 3.67 | Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Cantwell, BM; Dawes, PJ; Evans, RG; Farndon, J; Harris, AL; Needham, G; Sainsbury, JR; Wilson, R, 1986) |
| "In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation." | 3.67 | Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986) |
| "Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus replacement dose hydrocortisone." | 3.67 | Role of aminoglutethimide in male breast cancer. ( Dowsett, M; Harris, AL; Smith, IE; Stuart-Harris, R, 1986) |
| "A clinical phase II study was performed to evaluate the therapeutic efficacy of simultaneously administered aminoglutethimide and polychemotherapy in 31 patients with predominant bone metastases of breast cancer." | 3.67 | [Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer]. ( Dabag, S; Rieche, K; Scharlau, L, 1986) |
| "Only 13% of postmenopausal advanced breast cancer patients responded to endocrine treatment with aminoglutethimide plus danazol whilst 33% responded to aminoglutethimide alone, despite a similar suppression of serum oestradiol levels in the two groups." | 3.67 | Biochemical basis for the antagonism between aminoglutethimide and danazol in the endocrine treatment of breast cancer. ( Dowsett, M; Jeffcoate, SL; Murray, RM; Pitt, P, 1986) |
| "Eighteen premenopausal patients with progressive metastatic breast cancer were treated with aminoglutethimide (AG)/cortisone." | 3.67 | Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1986) |
| "Plasma levels of cholesterol, HDL cholesterol (HDL chol), LDL cholesterol (LDL chol), triglycerides, Al apoprotein and B apoprotein were studied in 73 patients receiving 500 mg aminoglutethimide (AG)/day and 40 mg hydrocortisone/day for advanced breast cancer." | 3.67 | [Aminoglutethimide-induced dyslipemia. Clinical study]. ( Bonneterre, J; Demaille, A; Fournier, C; Hecquet, B; Nguyen, M, 1985) |
| "Serum aminoglutethimide (AG) and N-acetylaminoglutethimide (NAG) concentrations were measured by high pressure liquid chromatography (HPLC) in 24 postmenopausal women with advanced breast cancer receiving increasing doses of oral AG." | 3.67 | Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer. ( Bradbrook, I; Morrison, P; Rogers, HJ; Smith, IE; Stuart-Harris, R, 1985) |
| "Aminoglutethimide without glucocorticoid has been shown to be a clinically effective treatment for postmenopausal breast cancer in low dosage (250 mg day-1)." | 3.67 | Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Santen, RJ; Santner, SJ; Smith, IE, 1985) |
| "Marked leukopenia and/or thrombocytopenia occurred in 12 of 1333 patients treated with aminoglutethimide (0." | 3.67 | Aminoglutethimide-induced hematologic toxicity: worldwide experience. ( Boucher, AE; Buzdar, AU; Harvey, HA; Henderson, IC; Lipton, A; Messeih, AA; Murray, R; Nagel, GA; Ragaz, J; Santen, RJ, 1985) |
| "Fifty-seven patients with actively progressing advanced breast cancer have been assessed for their response to low-dose aminoglutethimide (125 mg bd) without steroid replacement." | 3.67 | Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. ( Murray, R; Pitt, P, 1985) |
| "45 women (postmenopausal or after former oophorectomy) with metastatic breast cancer resistant to tamoxifen as well as to chemo- and radiotherapy were treated with aminoglutethimide (750 mg or 1000 mg resp." | 3.67 | [Aminoglutethimide therapy in advanced breast cancer]. ( Kühböck, J; Ludwig, H; Pötzi, P; Zielinski, C, 1985) |
| "Forty-five women with far-advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG), 1000 mg p." | 3.66 | Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1982) |
| "Sixty-five patients with advanced breast cancer, progressive despite prior endocrine therapy in all cases and prior chemotherapy in most cases, were treated with aminoglutethimide, 250 mg four times a day." | 3.66 | Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. ( Coates, AS; Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1982) |
| "Thirty-four postmenopausal patients with advanced breast cancer had an overall objective response rate of 47% when treated with aminoglutethimide and hydrocortisone initially and a response rate of 24% when crossed over to therapy with tamoxifen after progression on aminoglutethimide." | 3.66 | Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. ( Boucher, AE; Dixon, RJ; Harvey, HA; Lipton, A; Santen, RJ; Shafik, AS; White, DS, 1982) |
| "Thirty-eight metastatic breast cancer patients were treated with aminoglutethimide." | 3.66 | Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. ( Blumenschein, GR; Buzdar, AU; Legha, SS; Powell, KC, 1982) |
| "A group of 160 women with actively progressing metastatic breast cancer were treated with aminoglutethimide to induce medical adrenalectomy." | 3.66 | Aminoglutethimide in tamoxifen-resistant patients: The Melbourne Experience. ( Murray, RM; Pitt, P, 1982) |
| "Aminoglutethimide in combination with hydrocortisone provides an effective therapy in postmenopausal advanced breast cancer patients, with response rates of 37." | 3.66 | Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; McKinna, JA; Morgan, M; Smith, IE, 1982) |
| "In 114 patients with metastatic breast cancer resistant to chemo- and hormonal therapy another attempt was made to treat these patients with the hormone combination of aminoglutethimide (AG) 1000 mg daily and medroxyprogesteroneacetate (MAP) 1500 mg daily for 6 weeks, than 500 mg MAP daily." | 3.66 | [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force]. ( Blossey, HC; Nagel, GA; Wander, HE, 1982) |
| "We describe sequential response to aminoglutethimide after eventual failure of treatment with tamoxifen in a patient with metastatic breast cancer." | 3.66 | Response to aminoglutethimide after tamoxifen therapy in advanced breast cancer. ( Allison, RW; Furnival, CM; Lee, JF; Roberts, SJ, 1982) |
| "Sixty-five patients with actively progressing advanced breast cancer were treated with aminoglutethimide, a drug which inhibits adrenal steroid synthesis and decreases peripheral conversion of androgens to oestrogens." | 3.66 | Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. ( Jerums, G; Murray, RM; Pitt, P, 1981) |
| "Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone." | 3.66 | Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Powles, TJ; Smith, IE; White, H, 1983) |
| "Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy." | 3.66 | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1983) |
| "Serum prolactin concentrations were measured in 135 postmenopausal patients with advanced breast cancer prior to their treatment with one of 3 endocrine therapies: aminoglutethimide (AG), tamoxifen (T) + AG, or T + AG + danazol." | 3.66 | Prognostic significance of serum prolactin levels in advanced breast cancer. ( Coombes, RC; Dowsett, M; Harris, AL; Jeffcoate, SL; McGarrick, GE; Smith, IE, 1983) |
| "Seventy-one patients with breast cancer and bone metastases, together with other assessable sites of disease, were monitored by radiologic skeletal survey, bone scanning, pain charts, bone marrow aspirate, serum calcium, alkaline phosphatase and urine hydroxyproline/creatinine ratio." | 3.66 | Assessment of response of bone metastases to systemic treatment in patients with breast cancer. ( Coombes, RC; Dady, P; Ford, HT; Gazet, JC; McCready, VR; Parsons, C; Powles, TJ, 1983) |
| "During the last 2 years we have treated 24 patients (23 females and 1 male) with aminoglutethimide plus glucocorticoid for advanced breast cancer." | 3.66 | Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach. ( Dahl, O; Kvinnsland, S, 1983) |
| "Oestrogen receptor (ER) measurements in metastatic and primary tumours from patients with breast cancer have been correlated with the objective tumour response to treatment with aminoglutethimide (24 patients) or tamoxifen (39 patients)." | 3.66 | Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen. ( Holdaway, IM, 1981) |
| "Medical adrenalectomy, consisting of aminoglutethimide plus either dexamethasone or hydrocortisone, was administered to 53 women with advanced breast cancer." | 3.66 | Medical adrenalectomy in patients with advanced breast cancer. ( Brown, PW; Horsley, JS; Lawrence, W; Neifeld, JP; Newsome, HH; Terz, JJ, 1982) |
| "Aminoglutethimide in combination with dexamethasone has been used in 44 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptors." | 3.66 | Aminoglutethimide in the treatment of metastatic breast cancer. ( Troner, MB, 1982) |
| "A group of 213 unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide, 250 mg 4 times a day, and hydrocortisone, 20 mg 2 times a day." | 3.66 | Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. ( Harris, AL; Powles, TJ; Smith, IE, 1982) |
| "Aminoglutethimide was applied for treatment of 10 patients (8 postmenopausal, 2 ovariectomized) with metastasizing breast cancer." | 3.66 | [Treatment of metastasizing breast cancer with aminoglutethimide]. ( Aiginger, P; Kübböck, J; Linkesch, W; Ludwig, H; Pötzi, P, 1982) |
| "Seventy-three women with metastatic breast cancer were treated with aminoglutethimide and dexamethasone." | 3.66 | Treatment of metastatic breast cancer with aminoglutethimide. ( Asbury, RF; Bakemeier, RF; Bennett, JM; Fölsch, E; McCune, CS; Savlov, E, 1981) |
| "Fifty-three women with actively progressing advanced breast cancer, who had all previously received tamoxifen, were treated with aminoglutethimide to induce medical adrenalectomy." | 3.66 | Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment. ( Murray, RM; Pitt, P, 1981) |
| "Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women." | 3.66 | Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. ( Cox, CE; Harvey, HA; Lawrence, BV; Lipton, A; Santen, RJ; Smart, EK; Wells, SA; White, DS, 1980) |
| "Aminoglutethimide (AG) with Dexamethasone has been utilized in 26 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptor." | 3.66 | Aminoglutethimide in the management of metastatic breast cancer. ( Savaraj, N; Troner, MB, 1980) |
| "Aminoglutethimide and dexamethasone were administered for 3 months to 11 postmenopausal women with advanced breast cancer." | 3.66 | Medical adrenalectomy and plasma steroids in advanced breast carcinoma. ( Brown, PW; Lawrence, W; Newsome, HH; Terz, JJ, 1978) |
| "In conclusion, in a group of metastatic breast cancer patients, treated routinely by systemic therapies it was found, that the use of higher cut-off point for EGF-R positivity can improve the prediction of endocrine sensitivity." | 2.69 | Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. ( Branković-Magić, MV; Mitrovic, LB; Nesković-Konstantinović, ZB; Nikolić-Vukosavljević, DB; Spuzić, I, 2000) |
| " This report gives the results of a detailed pharmacokinetic and endocrine study of PyG in ten patients." | 2.67 | Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. ( Coombes, RC; Dowsett, M; Haynes, B; Jarman, M; Jones, A; Lonning, P; MacNeill, F; Mehta, A; Newton, C; Powles, TJ, 1991) |
| "Aminoglutethimide treatment caused significant alterations in the metabolite profiles of estradiol and estrone but with large interindividual variations." | 2.66 | Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide. ( Lønning, PE; Skulstad, P, 1989) |
| "Tamoxifen has become the most commonly used endocrine therapy of advanced breast cancer due to its few side effects and an overall response rate of 35%, which has been obtained in randomized trials of tamoxifen compared with either ablative, additive or inhibitive treatment approaches." | 2.66 | Endocrine therapy of advanced breast cancer. ( Mouridsen, HT; Rose, C, 1988) |
| " Patients were then treated with aminoglutethimide according to one of two dosage regimens: (a) aminoglutethimide 1000 mg/day + hydrocortisone 20 mg/day, and (b) aminoglutethimide 250 mg/day." | 2.66 | Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. ( Bezwoda, WR; Dansey, R; Mansoor, N, 1987) |
| "In postmenopausal women with breast carcinoma, plasma and urinary oestrogens remain detectable following surgical adrenalectomy or hypophysectomy." | 2.65 | Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy. ( Samojlik, E; Santen, RJ; Worgul, TJ, 1984) |
| "Aminoglutethimide (Elipten), at a dosage between 250 and 1500 mg/d by mouth, was administered in a clinical phase II study to 17 patients with metastasizing carcinoma of the breast resistant to hormones and cytostatic drugs." | 2.65 | [Aminoglutethimide in metastasizing carcinoma of the breast resistant to hormonal and cytostatic treatment (author's transl)]. ( Rieche, K, 1981) |
| "Anastrozole (Arimidex) was recently approved by the Food and Drug Administration for the adjuvant treatment of postmenopausal women with hormone-receptor-positive early breast cancer." | 2.42 | Aromatase inhibitors as adjuvant therapy in breast cancer. ( Davidson, NE; Visvanathan, K, 2003) |
| "Thus, management of metastatic breast cancer has largely shifted from surgeons to medical oncologists." | 2.40 | Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. ( Buzdar, AU; Roseman, BJ; Singletary, SE, 1997) |
| "Aminoglutethimide is an inhibitor of adrenal steroid biosynthesis and blocks the conversion of cholesterol to pregnenolone, and therefore reduces levels of adrenal androgens, which are a source of estrogens in both premenopausal and postmenopausal women." | 2.40 | [Aromatase inhibitors--new possibilities in treatment of breast carcinoma]. ( Friedrichs, K; Jänicke, F, 1998) |
| "Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks." | 2.40 | Use of aromatase inhibitors in breast carcinoma. ( Harvey, HA; Santen, RJ, 1999) |
| "Endocrine therapies for breast cancer have been used for more than a century." | 2.39 | Endocrine therapies of breast cancer. ( Gelber, RD; Goldhirsch, A, 1996) |
| " There is a tendency towards an increased response-rate with increased dosage of progestin, in both endometrial and breast carcinoma, while the route of administration appears to be of minor importance." | 2.37 | Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. ( Kauppila, A, 1984) |
| "Expectation of curing human breast cancer will likely require aggressive action at the time when the total body tumor burden is at a minimum." | 2.37 | Chemotherapy of breast cancer. ( Holland, JF; Perlow, LS, 1984) |
| "About one third of patients with breast cancer show objective improvement with aminoglutethimide, and it may also be of use in the treatment of adrenal carcinoma." | 2.37 | Aminoglutethimide and ketoconazole: historical perspectives and future prospects. ( Nicholls, PJ; Shaw, MA; Smith, HJ, 1988) |
| "Research using cell-lines of human breast cancer also suggests that anti-progestins and agents capable of antagonizing steroid-induced growth factors will inhibit tumour growth." | 2.37 | Fundamental research leading to improved endocrine therapy for breast cancer. ( Miller, WR, 1987) |
| "One-third of the cases of breast cancer in postmenopausal women are hormone-dependent and the lesions regress upon treatment with antiestrogens or inhibition of estrogen biosynthesis." | 2.37 | Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. ( Feil, PD; Leszczynski, D; Manni, A; Santen, RJ; Santner, SJ; Tilson-Mallet, N; Wright, C, 1986) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 2.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "This enzymatic shield protected the breast cancer cells from the antiproliferative action of GCS." | 1.30 | Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells. ( Bühler, H; Hundertmark, S; Ragosch, V; Rudolf, M; Weitzel, HK, 1997) |
| "3-fold) than that of R-AG and appears to be most likely the cause for the other pharmacokinetic differences observed." | 1.30 | Pharmacokinetics of S- and R-enantiomers of aminoglutethimide following oral administration of racemic drug in breast cancer patients. ( Abd el-Warith, A; Alshowaier, IA; el-Yazigi, A; Ezzat, A; Nicholls, PJ, 1999) |
| "Hormonal therapy of breast cancer is the oldest treatment in advanced disease." | 1.29 | Megestrol acetate in advanced breast carcinoma. ( Espie, M, 1994) |
| "Amplification of mdr-1 occurs in breast cancer patients receiving endocrine treatment." | 1.29 | Reduced occurrence of mdr-1 amplification in stage-IV breast-cancer patients treated with tamoxifen compared with other endocrine treatments. ( Lönn, S; Lönn, U; Stenkvist, B, 1993) |
| "Aromatase activity was measured in (i) breast cancers by incubating tumour homogenates with [7 alpha 3H]testosterone and characterizing the production of radioactively-labelled oestradiol and (ii) breast fat by incubation of sub-cellular fractions of fibroblast cell lines with [1 beta 3H]androstenedione and monitoring the formation of 3H2O." | 1.29 | Factors influencing aromatase activity in the breast. ( Miller, WR; Mullen, P, 1993) |
| "Of 221 patients with breast cancer of known epidermal growth factor receptor (EGFR) and oestrogen receptor (ER) status, 99 had developed recurrences during the period of follow-up (range 3-60 months, median 24 months)." | 1.28 | Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. ( Angus, B; Cairns, J; Farndon, J; Harris, AL; Horne, CH; Nicholson, S; Sainsbury, JR; Wright, C, 1992) |
| "As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer." | 1.28 | [The use of aminoglutethimide in the treatment of metastatic breast cancer]. ( Bellora, MG; Bergamino, T; Ciancio, A; Ferrero, A; Sismondi, P; Zola, P, 1991) |
| " On subsequent repeated dosing with PyG, both the Km (4." | 1.28 | Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. ( Coombes, RC; Dowsett, M; Griggs, LJ; Haynes, BP; Jarman, M; Jones, A; Lønning, PE; Mehta, A; Powles, T; Stein, R, 1991) |
| "A total of 34 patients with advanced breast cancer entered the study: 17 were given 1,000 mg/day and 17 received 500 mg/day for at least 3 months." | 1.28 | Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses. ( Ambroso, G; Balli, M; Bonciarelli, G; Camaggi, CM; Cellerino, R; Indelli, M; Malacarne, P; Martoni, A; Miseria, S; Strocchi, E, 1991) |
| " Adrenal failure due to glucocorticoid deficiency was also present and required an increased dosage of cortisone." | 1.28 | Aminoglutethimide-induced hyperkalaemia. ( Bentley, P; Davies, JP; Ghose, RR, 1989) |
| "Hormonotherapy of metastatic breast cancer was begun in 1896." | 1.28 | [Current status of hormonotherapy of metastatic cancer of the breast]. ( Namer, M, 1989) |
| " This dosage regimen appears of comparable efficacy to previously reported higher dosage regimens with reduced toxicity compared to low dose regimens without hydrocortisone." | 1.28 | Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. ( Cantwell, BM; Carmichael, J; Dawes, P; Farndon, J; Harris, AL; Robinson, A; Wilson, R, 1989) |
| "Two case reports are described, both breast carcinoma patients with metastatic disease." | 1.27 | A call for caution in the use of aminoglutethimide: negative interactions with dexamethasone and beta blocker treatment. ( Baerwald, H; Catane, R; Halpern, J, 1984) |
| "Tamoxifen was tried in three patients after relapse following adrenalectomy; all three patients responded with a mean duration of 9 months." | 1.27 | Metastatic breast cancer in males. Assessment of endocrine therapy. ( Dao, TL; Nemoto, T; Patel, JK, 1984) |
| "In 57 patients with metastasized breast carcinoma, serum CEA levels (CEA-Ria-Kit, Abbot) were correlated with the clinical course under endocrine or cytostatic therapy." | 1.27 | [Prognostic value of serum CEA and therapy-induced nonspecific CEA levels in metastasizing breast carcinoma]. ( Garbrecht, M; Kleeberg, UR; Müllerleile, U; Pompecki, R; Treidler, J, 1984) |
| "Patients with advanced, evaluable breast cancer were biopsied before the start of endocrine treatment, and ER and cAR measurements were performed." | 1.27 | Relationship of cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human breast cancer. ( Døskeland, SO; Ekanger, R; Kvinnsland, S; Thorsen, T, 1983) |
| "Antipyrine was given as a single test dose before and after 3 mo of AG treatment, whereas theophylline and digitoxin kinetics were investigated at steady state in patients receiving these drugs therapeutically before and after AG therapy." | 1.27 | Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer. ( Bakke, OM; Kvinnsland, S; Lønning, E, 1984) |
| "Human breast carcinomas contain aromatase, the enzyme necessary for the conversion of androgens to estrogens." | 1.27 | Biological significance of aromatase activity in human breast tumors. ( Feil, PD; Santen, RJ; Santner, SJ; Tilson-Mallett, N, 1983) |
| "14 males with disseminated cancer of breast received a total of 35 endocrine trials, mainly in the form of hormonal supplementation." | 1.27 | Hormonal treatment of disseminated male breast cancer. ( Di Lauro, L; Lazzaro, B; Lopez, M; Papaldo, P, 1985) |
| "Aminoglutethimide (Ag) has been used in different dosages with and without combined treatment with glucocorticoids for the suppression of peripheral plasma levels of steroidal hormones." | 1.27 | Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer. ( Alexieva-Figusch, J; de Jong, FH; Klign, JG; Lamberts, WJ; van Gilse, HA, 1987) |
| "Endocrine therapy of breast cancer was reviewed historically, and growth or regression of the tumor in relation to estrogen level in pheripheral blood was elucidated." | 1.27 | [Recent progress in endocrine therapy of patients with breast cancer]. ( Tominaga, T, 1988) |
| "A total of 79 patients with metastatic breast cancer entered the study, and their plasma and urine samples were analyzed by high-performance liquid chromatography (HPLC)." | 1.27 | Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ( Höffken, K; Miller, AA; Miller, BE; Schmidt, CG, 1987) |
| "In order to mimic postmenopausal breast cancer, we ovariectomized rats after N-methyl-N-nitrosourea administration." | 1.27 | Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. ( Coombes, RC; Easton, D; Goss, PE; Singh, D; Wilkinson, JR; Williams, JC, 1986) |
| "A 54-year-old woman had a primary breast cancer with an estrogen receptor of 11." | 1.27 | Response to aminoglutethimide after failure of tamoxifen therapy in breast cancer. ( Carter, RD; Muchmore, JH; Sutherland, CM, 1985) |
| "Of the common tumors, breast cancer is the most responsive to a wide variety of cancer chemotherapeutic agents." | 1.27 | Update in cancer chemotherapy: general considerations and breast cancer, Part I. ( Wright, JC, 1985) |
| "Its role in the biology of breast cancer is unclear." | 1.26 | Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ( Bird, CE; Clark, AF; Masters, V; Sterns, EE, 1982) |
| "In the therapy of metastatic breast cancer with high dose MAP the cortisol like effect could be shown even in long term treatment." | 1.26 | [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer]. ( Blossey, HC; Kleeberg, U; Köbberling, J; Nagel, GA; Wander, HE, 1982) |
| "Aminoglutethimide (AG) is a potent inhibitor of aromatization in placental microsomes and in peripheral tissues in postmenopausal women." | 1.26 | Resistance of the ovary to blockade of aromatization with aminoglutethimide. ( Samojlik, E; Santen, RJ; Wells, SA, 1980) |
| "Hormone-dependent breast carcinomas respond to deprivation of biologically active estrogens with objectively quantifiable tumor regression." | 1.26 | Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. ( Boucher, A; Harvey, H; Lipton, A; Samojlik, E; Santen, RJ; Wells, SA; Worgul, TJ, 1982) |
| " These findings led to development of a practical regimen of escalating aminoglutethimide dosage in combination with hydrocortisone for treatment of patients with breast carcinoma." | 1.26 | In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. ( Rosen, HR; Samojlik, E; Santen, RJ; Santner, SJ; Tilsen-Mallett, N; Veldhuis, JD, 1982) |
| "Forty patients with advanced breast cancer have been treated by endocrine therapy." | 1.26 | Significance of aromatase activity in human breast cancer. ( Forrest, AP; Hawkins, RA; Miller, WR, 1982) |
| "Human breast neoplasms can be divided into hormone-dependent and hormone-independent subtypes." | 1.26 | Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. ( Boucher, AE; Harvey, H; Lipton, A; Samojlik, E; Santen, RJ; Worgul, TJ, 1982) |
| "Aminoglutethimide is an inhibitor of various steroid hydroxylation reactions in the adrenal gland, the ovary, the testis and the placenta; furthermore, the extraglandular estrogen synthesis is inhibited by blocking the aromatase in the subcutaneous fatty tissue." | 1.26 | [Aminoglutethimide - a new drug for the after care in breast cancer]. ( Rabe, D; Rabe, T; Runnebaum, B, 1981) |
| "42 patients with metastatic breast carcinoma were treated with aminoglutethimide, which inhibits adrenal steroid hormone synthesis." | 1.26 | Aminoglutethimide in treatment of metastatic breast carcinoma. ( Fahmy, DR; Fitzharris, BM; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Neville, AM; Powles, TJ; Smith, IE, 1978) |
| "Aminoglutethimide is an investigational agent of proven benefit in the treatment of metastatic breast carcinoma." | 1.26 | Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. ( Hamilton, R; Harvey, HA; Lawrence, B; Lipton, A; Mercurio, T; Santen, RJ, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 303 (67.79) | 18.7374 |
| 1990's | 112 (25.06) | 18.2507 |
| 2000's | 27 (6.04) | 29.6817 |
| 2010's | 4 (0.89) | 24.3611 |
| 2020's | 1 (0.22) | 2.80 |
| Authors | Studies |
|---|---|
| Su, B | 2 |
| Hackett, JC | 1 |
| Díaz-Cruz, ES | 1 |
| Kim, YW | 1 |
| Brueggemeier, RW | 2 |
| Balunas, MJ | 1 |
| Landini, S | 1 |
| Kinghorn, AD | 1 |
| Maiti, A | 1 |
| Cuendet, M | 1 |
| Croy, VL | 1 |
| Endringer, DC | 1 |
| Pezzuto, JM | 1 |
| Cushman, M | 1 |
| Lézé, MP | 1 |
| Palusczak, A | 1 |
| Hartmann, RW | 1 |
| Le Borgne, M | 1 |
| Neves, MA | 1 |
| Dinis, TC | 1 |
| Colombo, G | 1 |
| Sá e Melo, ML | 1 |
| Muftuoglu, Y | 1 |
| Mustata, G | 1 |
| Yadav, MR | 1 |
| Barmade, MA | 1 |
| Tamboli, RS | 1 |
| Murumkar, PR | 1 |
| Khan, MZI | 1 |
| Uzair, M | 1 |
| Nazli, A | 1 |
| Chen, JZ | 1 |
| Pfeiler, G | 1 |
| Stöger, H | 1 |
| Dubsky, P | 1 |
| Mlineritsch, B | 3 |
| Singer, C | 2 |
| Balic, M | 1 |
| Fitzal, F | 1 |
| Moik, M | 1 |
| Kwasny, W | 4 |
| Selim, U | 1 |
| Renner, K | 2 |
| Ploner, F | 1 |
| Steger, GG | 1 |
| Seifert, M | 2 |
| Hofbauer, F | 2 |
| Sandbichler, P | 1 |
| Samonigg, H | 4 |
| Jakesz, R | 4 |
| Greil, R | 3 |
| Fesl, C | 1 |
| Gnant, M | 3 |
| Kadhirvel, P | 1 |
| Azenha, M | 1 |
| Schillinger, E | 1 |
| Halhalli, MR | 1 |
| Silva, AF | 1 |
| Sellergren, B | 1 |
| Hill, J | 1 |
| Moore, H | 1 |
| Mustacchi, G | 2 |
| Muggia, M | 1 |
| Milani, S | 1 |
| Ceccherini, R | 1 |
| Leita, ML | 1 |
| Dellach, C | 1 |
| Schmid, M | 2 |
| Kubista, E | 2 |
| Menzel, C | 1 |
| Haider, K | 1 |
| Taucher, S | 1 |
| Steindorfer, P | 1 |
| Stierer, M | 3 |
| Tausch, C | 2 |
| Fridrik, M | 1 |
| Wette, V | 1 |
| Steger, G | 1 |
| Hausmaninger, H | 1 |
| Visvanathan, K | 1 |
| Davidson, NE | 1 |
| Vogel, CL | 1 |
| Rose, C | 5 |
| Vicent, MJ | 2 |
| Greco, F | 2 |
| Nicholson, RI | 4 |
| Paul, A | 1 |
| Griffiths, PC | 1 |
| Duncan, R | 2 |
| Martínez-Campa, C | 1 |
| González, A | 1 |
| Mediavilla, MD | 1 |
| Alonso-González, C | 1 |
| Sánchez-Barceló, EJ | 1 |
| Cos, S | 1 |
| Mauri, D | 1 |
| Pavlidis, N | 1 |
| Polyzos, NP | 1 |
| Ioannidis, JP | 1 |
| Gee, S | 1 |
| Jones, AT | 1 |
| Gee, J | 1 |
| Dutta, U | 1 |
| Pant, K | 1 |
| Prowell, TM | 1 |
| Stearns, V | 1 |
| Dadak, C | 1 |
| Rücklinger, E | 1 |
| Rudas, M | 1 |
| Lehnert, M | 1 |
| Huynh, A | 1 |
| Lax, S | 1 |
| Schippinger, W | 1 |
| Dietze, O | 1 |
| Stiglbauer, W | 1 |
| Grill, R | 1 |
| Gnant, MF | 1 |
| Filipits, M | 1 |
| Bruning, PF | 6 |
| Bonfrer, JM | 4 |
| De Jong-Bakker, M | 3 |
| Nooyen, W | 2 |
| Kvinnsland, S | 13 |
| Lønning, PE | 27 |
| Dahl, O | 2 |
| Nagel, GA | 8 |
| Wander, HE | 8 |
| Blossey, HC | 6 |
| Bonneterre, J | 11 |
| Nguyen, M | 4 |
| Hecquet, B | 4 |
| Cappelaere, P | 4 |
| Powles, TJ | 23 |
| Ashley, S | 1 |
| Ford, HT | 11 |
| Gazet, JC | 12 |
| Nash, AG | 4 |
| Neville, AM | 4 |
| Coombes, RC | 19 |
| Stuart-Harris, R | 8 |
| Dowsett, M | 32 |
| Bozek, T | 1 |
| McKinna, JA | 9 |
| Jeffcoate, SL | 13 |
| Kurkure, A | 1 |
| Carr, L | 2 |
| Smith, IE | 35 |
| Halpern, J | 1 |
| Catane, R | 1 |
| Baerwald, H | 1 |
| Gale, KE | 3 |
| Kaye, SB | 2 |
| Woods, RL | 2 |
| Fox, RM | 2 |
| Coates, AS | 1 |
| Tattersall, MH | 2 |
| Harvey, HA | 13 |
| Lipton, A | 21 |
| White, DS | 4 |
| Santen, RJ | 49 |
| Boucher, AE | 7 |
| Shafik, AS | 1 |
| Dixon, RJ | 1 |
| Buzdar, AU | 6 |
| Powell, KC | 2 |
| Legha, SS | 1 |
| Blumenschein, GR | 2 |
| Onnis, A | 1 |
| Graziottin, A | 1 |
| Velasco, M | 1 |
| Marchetti, M | 1 |
| Patel, JK | 2 |
| Nemoto, T | 3 |
| Dao, TL | 2 |
| Paridaens, R | 5 |
| Leclercq, G | 1 |
| Heuson, JC | 5 |
| Chilvers, C | 3 |
| Bettelheim, R | 2 |
| Gordon, C | 2 |
| Zava, D | 1 |
| Abul-Hajj, YJ | 2 |
| Murray, RM | 5 |
| Pitt, P | 7 |
| Harris, AL | 27 |
| Morgan, M | 5 |
| Ingle, JN | 3 |
| Battelli, T | 1 |
| Manocchi, P | 1 |
| Guistini, L | 1 |
| Mattioli, R | 1 |
| Ginnetti, A | 1 |
| Jeffcoate, S | 2 |
| Scaglia, HE | 1 |
| Koliren, L | 1 |
| Loruso, A | 1 |
| Zylbersztein, C | 1 |
| Ramos, G | 1 |
| Díaz, L | 1 |
| Soto, E | 1 |
| Carlström, K | 3 |
| Döberl, A | 1 |
| Pousette, A | 2 |
| Rannevik, G | 2 |
| Wilking, N | 3 |
| Kauppila, A | 1 |
| Stuart-Harris, RC | 1 |
| Treidler, J | 1 |
| Pompecki, R | 1 |
| Müllerleile, U | 1 |
| Garbrecht, M | 1 |
| Kleeberg, UR | 2 |
| Wells, SA | 17 |
| Hayward, JL | 1 |
| Taylor, RE | 1 |
| Humphreys, J | 1 |
| Casey, AJ | 1 |
| Allison, RW | 1 |
| Furnival, CM | 1 |
| Lee, JF | 1 |
| Roberts, SJ | 1 |
| Bird, CE | 2 |
| Masters, V | 1 |
| Sterns, EE | 2 |
| Clark, AF | 1 |
| Köbberling, J | 1 |
| Kleeberg, U | 2 |
| Beccati, MD | 1 |
| Degli Azzi Vitelleschi, I | 1 |
| Marangolo, M | 1 |
| Samojlik, E | 18 |
| Worgul, TJ | 6 |
| Ekanger, R | 1 |
| Døskeland, SO | 1 |
| Thorsen, T | 6 |
| Cikes, M | 1 |
| Drees, N | 1 |
| Mouridsen, HT | 4 |
| Palshof, T | 1 |
| Mattheiem, W | 1 |
| Sylvester, RJ | 2 |
| Rotmensz, N | 2 |
| Paridaens, RJ | 2 |
| Markham, G | 1 |
| Moiseenko, VM | 4 |
| Semiglazov, VF | 4 |
| Perlow, LS | 1 |
| Holland, JF | 1 |
| White, H | 4 |
| Harmer, CL | 3 |
| Mason, RC | 1 |
| Chetty, U | 4 |
| Miller, WR | 7 |
| Hawkins, RA | 5 |
| Forrest, AP | 8 |
| Jerums, G | 1 |
| Katz, ME | 1 |
| Young, JA | 1 |
| Newcomer, LN | 1 |
| Keller, AM | 2 |
| Bezwoda, WR | 4 |
| Derman, DP | 1 |
| Browde, S | 2 |
| Goss, G | 1 |
| Lange, M | 1 |
| Lønning, E | 1 |
| Bakke, OM | 1 |
| Gez, E | 1 |
| Sulkes, A | 1 |
| Bonfrèr, JG | 1 |
| Engelsman, E | 1 |
| Hamersma-vd Linden, E | 1 |
| Kampel, LJ | 1 |
| Kurman, MR | 1 |
| Brufman, G | 3 |
| Biran, S | 3 |
| Josephsen, PG | 1 |
| Pedersen, C | 1 |
| Appelgren, LE | 1 |
| Wallgren, A | 1 |
| Theve, T | 1 |
| Tilson-Mallett, N | 1 |
| Santner, SJ | 5 |
| Feil, PD | 2 |
| Parsons, CA | 2 |
| Mitchell, MD | 1 |
| Henahan, J | 1 |
| Schanche, JS | 1 |
| Ueland, PM | 5 |
| Boucher, A | 3 |
| White, D | 3 |
| Bernath, A | 2 |
| Dixon, R | 2 |
| Richards, G | 2 |
| Shafik, A | 2 |
| Szepesi, T | 1 |
| Schratter-Sehn, AU | 1 |
| Villardo, A | 1 |
| Walsh, G | 1 |
| Williams, C | 1 |
| Buchanan, R | 1 |
| Lowenbraun, S | 1 |
| Cunitz, D | 1 |
| McGarrick, GE | 1 |
| Dady, P | 1 |
| Parsons, C | 1 |
| McCready, VR | 1 |
| Kissin, MW | 1 |
| Kark, AE | 1 |
| Holdaway, IM | 1 |
| Veldhuis, JD | 2 |
| Anderson, JL | 1 |
| Phillipou, G | 1 |
| Black, RB | 1 |
| Interrante, A | 1 |
| Smart, E | 3 |
| Cox, C | 2 |
| Corkery, J | 1 |
| Leonard, RC | 3 |
| Henderson, IC | 5 |
| Gelman, RS | 1 |
| Hourihan, J | 1 |
| Ascoli, DM | 1 |
| Salhanick, HA | 2 |
| Harvey, H | 8 |
| Green, SJ | 3 |
| Ahmann, DL | 2 |
| Edmonson, JH | 2 |
| Nichols, WC | 1 |
| Frytak, S | 1 |
| Rubin, J | 2 |
| Horsley, JS | 1 |
| Newsome, HH | 3 |
| Brown, PW | 4 |
| Neifeld, JP | 1 |
| Terz, JJ | 4 |
| Lawrence, W | 3 |
| Brodie, AM | 4 |
| Kirschner, MA | 1 |
| Ertel, NH | 1 |
| Tilsen-Mallett, N | 1 |
| Rosen, HR | 1 |
| MacIndoe, JH | 1 |
| Woods, GR | 1 |
| Etre, LA | 1 |
| Covey, DF | 1 |
| Troner, MB | 2 |
| Rees, LH | 1 |
| Ratcliffe, WA | 1 |
| Henk, M | 1 |
| Costanza, ME | 1 |
| Minasian, H | 1 |
| Bamber, JC | 1 |
| Austerlitz, J | 1 |
| Mackie, KW | 1 |
| Kübböck, J | 1 |
| Ludwig, H | 4 |
| Aiginger, P | 1 |
| Linkesch, W | 1 |
| Pötzi, P | 2 |
| Asbury, RF | 1 |
| Bakemeier, RF | 1 |
| Fölsch, E | 1 |
| McCune, CS | 1 |
| Savlov, E | 1 |
| Bennett, JM | 1 |
| Rieche, K | 2 |
| Rabe, T | 1 |
| Rabe, D | 1 |
| Runnebaum, B | 1 |
| Van Haelen, C | 1 |
| Harmer, C | 1 |
| Jones, M | 1 |
| Canellos, GP | 1 |
| Lawrence, BV | 1 |
| Cox, CE | 2 |
| Smart, EK | 1 |
| Check, WA | 1 |
| McCraken, M | 1 |
| Benson, EA | 1 |
| Hickling, P | 2 |
| Savaraj, N | 1 |
| Barry, WF | 1 |
| Haagensen, DE | 3 |
| Ivanov, VG | 3 |
| Bershteĭn, LM | 2 |
| Ivanova, OA | 3 |
| Tsyrlina, EV | 3 |
| Barash, NIu | 1 |
| Bozhok, AA | 3 |
| Murray, R | 4 |
| Williams, CJ | 2 |
| Barley, VL | 2 |
| Blackledge, GR | 2 |
| Rowland, CG | 2 |
| Tyrrell, CJ | 2 |
| Bachelot, F | 1 |
| Dermaille, A | 1 |
| Fargeot, P | 5 |
| Namer, M | 3 |
| Pouillart, J | 1 |
| Espié, M | 2 |
| Wojtacki, J | 1 |
| Dziewulska-Bokiniec, A | 1 |
| Czech, I | 1 |
| Vanden Bossche, HV | 1 |
| Moereels, H | 1 |
| Koymans, LM | 1 |
| Cocconi, G | 3 |
| Garcia-Giralt, E | 2 |
| Omodei Zorini, C | 2 |
| Ferri, L | 1 |
| Ayme, Y | 2 |
| Carton, M | 2 |
| Daban, A | 2 |
| Delozier, T | 2 |
| Fumoleau, P | 2 |
| Gorins, A | 2 |
| Manni, A | 5 |
| Steinberg, JL | 1 |
| Trudeau, ME | 2 |
| Lönn, U | 3 |
| Lönn, S | 3 |
| Stenkvist, B | 3 |
| Etherington, J | 1 |
| Haynes, P | 1 |
| Buchanan, N | 1 |
| MacNeill, FA | 2 |
| Jacobs, S | 4 |
| Carella, MJ | 1 |
| Dimitrov, NV | 1 |
| Gossain, VV | 1 |
| Srivastava, L | 1 |
| Rovner, DR | 1 |
| Pronzato, P | 4 |
| Rubagotti, A | 2 |
| Amoroso, D | 3 |
| Bertelli, G | 3 |
| Queirolo, P | 1 |
| Sertoli, MR | 1 |
| Rosso, M | 2 |
| Gallotti, P | 1 |
| Monzeglio, C | 1 |
| Rosso, R | 2 |
| Andersen, JW | 1 |
| Tormey, DC | 4 |
| Mansour, EG | 1 |
| Davis, TE | 1 |
| Horton, J | 2 |
| Wolter, JM | 1 |
| Smith, TJ | 1 |
| Cummings, FJ | 1 |
| Mercer, PM | 1 |
| Ebbs, SR | 1 |
| Fraser, SC | 1 |
| Coltart, RS | 1 |
| Bates, T | 1 |
| Mullen, P | 1 |
| Iveson, TJ | 1 |
| Ahern, J | 1 |
| Guerin, D | 1 |
| Guerin, R | 1 |
| Stein, M | 1 |
| Kitawaki, J | 2 |
| Kim, T | 1 |
| Kanno, H | 1 |
| Noguchi, T | 1 |
| Yamamoto, T | 2 |
| Okada, H | 2 |
| Adenis, A | 1 |
| Pion, JM | 2 |
| Cambier, L | 1 |
| Kamus, E | 1 |
| Höffken, K | 5 |
| Ekse, D | 5 |
| Alshowaier, IA | 2 |
| el-Yazigi, A | 2 |
| Ezzat, A | 2 |
| el-Warith, AA | 1 |
| Nicholls, PJ | 4 |
| Goldhirsch, A | 2 |
| Gelber, RD | 1 |
| Ingelman-Sundberg, H | 1 |
| Nilsson, B | 1 |
| Frost, VJ | 1 |
| Helle, SI | 1 |
| van der Stappen, JW | 1 |
| Holly, JM | 1 |
| Lien, EA | 3 |
| Anker, G | 2 |
| Refsum, H | 2 |
| Geisler, J | 1 |
| Johannessen, DC | 7 |
| Barash, NI | 1 |
| Popova, RT | 1 |
| Migmanova, NS | 1 |
| Seleznev, IK | 1 |
| Hultborn, R | 1 |
| Johansson-Terje, I | 1 |
| Bergh, J | 1 |
| Glas, U | 1 |
| Hallsten, L | 1 |
| Hatschek, T | 1 |
| Holmberg, E | 1 |
| Ideström, K | 1 |
| Norberg, B | 1 |
| Ranstam, J | 1 |
| Söderberg, M | 1 |
| Wallgren, UB | 1 |
| Russell, CA | 1 |
| O'Sullivan, J | 1 |
| Hynes, HE | 1 |
| Budd, GT | 1 |
| Congdon, JE | 1 |
| Martino, S | 1 |
| Osborne, CK | 1 |
| Tekmal, RR | 1 |
| Durgam, VR | 1 |
| Roseman, BJ | 1 |
| Singletary, SE | 1 |
| Rubens, RD | 1 |
| Cameron, DA | 1 |
| Anderson, ED | 3 |
| Levack, P | 1 |
| Anderson, TJ | 3 |
| Cheung, KL | 1 |
| Willsher, PC | 1 |
| Pinder, SE | 1 |
| Ellis, IO | 1 |
| Elston, CW | 1 |
| Blamey, RW | 1 |
| Robertson, JF | 1 |
| Hundertmark, S | 1 |
| Bühler, H | 1 |
| Rudolf, M | 1 |
| Weitzel, HK | 1 |
| Ragosch, V | 1 |
| Kaufmann, M | 1 |
| Leriche, N | 1 |
| Thürlimann, B | 1 |
| Serin, D | 1 |
| Roché, H | 1 |
| di Salle, E | 1 |
| Lanzalone, S | 1 |
| Zurlo, MG | 1 |
| Piscitelli, G | 1 |
| Berntsen, H | 1 |
| Netteland, B | 1 |
| Berge, R | 1 |
| Svardal, A | 1 |
| Friedrichs, K | 1 |
| Jänicke, F | 1 |
| Gershanovich, M | 2 |
| Chaudri, HA | 1 |
| Campos, D | 2 |
| Lurie, H | 2 |
| Bonaventura, A | 2 |
| Jeffrey, M | 2 |
| Buzzi, F | 2 |
| Bodrogi, I | 2 |
| Reichardt, P | 1 |
| O'Higgins, N | 1 |
| Romieu, G | 2 |
| Friederich, P | 1 |
| Lassus, M | 2 |
| Bell, SC | 1 |
| Anderson, EG | 1 |
| Anker, GB | 1 |
| Lonning, PE | 2 |
| de Jong, PC | 1 |
| Blijham, GH | 2 |
| Chaudri, Kh | 1 |
| Reichard, P | 1 |
| O'Higgins, NO | 1 |
| Friedrich, P | 1 |
| Feutrie, ML | 1 |
| Abd el-Warith, A | 1 |
| Ragaz, J | 2 |
| Kamby, C | 3 |
| Andersson, M | 1 |
| Bastholt, L | 2 |
| Møller, KA | 1 |
| Andersen, J | 2 |
| Munkholm, P | 1 |
| Dombernowsky, P | 2 |
| Christensen, IJ | 1 |
| Nesković-Konstantinović, ZB | 1 |
| Nikolić-Vukosavljević, DB | 1 |
| Branković-Magić, MV | 1 |
| Mitrovic, LB | 1 |
| Spuzić, I | 1 |
| Boccardo, F | 1 |
| Mesiti, M | 1 |
| Romeo, D | 1 |
| Caroti, C | 1 |
| Farris, A | 1 |
| Cruciani, G | 1 |
| Villa, E | 1 |
| Schieppati, G | 1 |
| Morris, KT | 1 |
| Toth-Fejel, S | 1 |
| Schmidt, J | 1 |
| Fletcher, WS | 1 |
| Pommier, RF | 1 |
| Soudon, J | 1 |
| Porpiglia, M | 1 |
| Genta, F | 1 |
| Vicelli, R | 1 |
| De Nicola, B | 1 |
| Ferraris, F | 1 |
| Piccinno, R | 1 |
| Benedetto, C | 1 |
| Fitzharris, BM | 1 |
| Fahmy, DR | 1 |
| Roberts, MM | 1 |
| Stewart, HJ | 2 |
| Veldhuis, J | 2 |
| Maass, H | 2 |
| Jonat, W | 2 |
| Ruby, EB | 1 |
| Kendall, J | 2 |
| Runić, S | 1 |
| Gupta, C | 2 |
| Rudy, EB | 1 |
| McGuire, WL | 1 |
| Chamness, GC | 1 |
| Horwitz, KB | 1 |
| Zava, DT | 1 |
| Honn, KV | 1 |
| Chavin, W | 1 |
| Lawrence, B | 1 |
| Hamilton, R | 1 |
| Mercurio, T | 1 |
| Santner, S | 2 |
| Davis, B | 1 |
| Ruby, E | 1 |
| Osterman, J | 2 |
| Kardinal, CG | 1 |
| Donegan, WL | 1 |
| Cohn, N | 1 |
| Demers, LM | 2 |
| Misbin, RI | 1 |
| Foltz, EL | 1 |
| Santen, R | 1 |
| Bardin, CW | 1 |
| Ruby, EJ | 1 |
| Dilley, WG | 1 |
| Koelmeyer, TD | 1 |
| Stephens, EJ | 1 |
| Wood, HF | 1 |
| Misbin, RJ | 1 |
| Misbin, R | 1 |
| Foa, PP | 1 |
| Corder, MP | 1 |
| Flannery, EP | 1 |
| Wright, C | 2 |
| Nicholson, S | 4 |
| Angus, B | 2 |
| Sainsbury, JR | 5 |
| Farndon, J | 4 |
| Cairns, J | 1 |
| Horne, CH | 1 |
| Pritchard, KI | 1 |
| Pérez, N | 1 |
| Borja, J | 1 |
| Jones, AL | 2 |
| Law, M | 1 |
| Tidy, A | 1 |
| Easton, D | 4 |
| Nash, A | 1 |
| Hisamatsu, K | 1 |
| Nomura, Y | 1 |
| Tashiro, H | 1 |
| Jones, A | 3 |
| McNeil, F | 1 |
| Aakvaag, A | 2 |
| Kahán, Z | 1 |
| Tóth, I | 1 |
| Vecsernyés, M | 1 |
| Bisagni, G | 2 |
| Ceci, G | 2 |
| Bacchi, M | 1 |
| Boni, C | 1 |
| Brugia, M | 1 |
| Carpi, A | 1 |
| Di Costanzo, F | 1 |
| Franciosi, V | 1 |
| Gori, S | 1 |
| Abe, K | 1 |
| Mehta, A | 3 |
| Cantwell, BM | 5 |
| Haynes, B | 2 |
| Griggs, L | 1 |
| Schmidt, UM | 2 |
| Brockmann, B | 1 |
| Geschke, E | 1 |
| Clavel, M | 1 |
| Poon, GK | 1 |
| McCague, R | 1 |
| Griggs, LJ | 3 |
| Jarman, M | 4 |
| Lewis, IA | 1 |
| Bellora, MG | 1 |
| Ciancio, A | 1 |
| Ferrero, A | 1 |
| Bergamino, T | 1 |
| Zola, P | 1 |
| Sismondi, P | 1 |
| Focan, C | 1 |
| Fukuoka, M | 1 |
| Haynes, BP | 1 |
| Powles, T | 1 |
| Stein, R | 1 |
| Henry, JA | 1 |
| Piggott, NH | 1 |
| Mallick, UK | 1 |
| Farndon, JR | 3 |
| Westley, BR | 1 |
| May, FE | 1 |
| Aboul-Enein, HY | 1 |
| Islam, MR | 1 |
| MacNeill, F | 1 |
| Newton, C | 1 |
| Lonning, P | 1 |
| Strocchi, E | 1 |
| Camaggi, CM | 1 |
| Martoni, A | 1 |
| Cellerino, R | 1 |
| Miseria, S | 1 |
| Malacarne, P | 1 |
| Indelli, M | 1 |
| Balli, M | 1 |
| Bonciarelli, G | 1 |
| Ambroso, G | 2 |
| Garcia Giralt, E | 1 |
| Voznyĭ, EK | 1 |
| Meshcheriakova, NG | 1 |
| Biakhov, MIu | 1 |
| Vasiuta, NIu | 1 |
| Hardy, JR | 1 |
| Judson, IR | 1 |
| Sinnett, HD | 1 |
| Ashley, SE | 1 |
| Ellin, CL | 1 |
| von Matthiessen, H | 1 |
| Distler, W | 1 |
| Halpenny, O | 1 |
| Bye, A | 1 |
| Cranny, A | 1 |
| Feely, J | 1 |
| Daly, PA | 1 |
| Wildiers, J | 1 |
| Jassem, J | 1 |
| Beex, LV | 1 |
| Schornagel, J | 1 |
| Nooijen, WJ | 2 |
| Vanek, N | 1 |
| Hortobagyi, GN | 1 |
| Lundgren, S | 3 |
| Stier, G | 1 |
| Gürtler, R | 1 |
| Müller, U | 1 |
| Tanneberger, S | 1 |
| Labrie, F | 1 |
| Dupont, A | 1 |
| Bélanger, A | 1 |
| Lacourcière, Y | 1 |
| Béland, L | 1 |
| Cusan, L | 1 |
| Lachance, R | 1 |
| Jack, WJ | 1 |
| Julien, JP | 2 |
| Veyret, C | 1 |
| van Zijl, J | 1 |
| Klijn, JG | 1 |
| Mignolet, F | 1 |
| Seymour, L | 1 |
| Meyer, K | 1 |
| Kondrat'ev, VB | 1 |
| Dil'man, VM | 2 |
| McClelland, RA | 1 |
| Berger, U | 1 |
| Miller, LS | 1 |
| Halcrow, P | 2 |
| Chambers, P | 2 |
| Rosner, D | 1 |
| Levack, PA | 1 |
| Davies, JP | 1 |
| Bentley, P | 1 |
| Ghose, RR | 1 |
| Skulstad, P | 2 |
| Sunde, A | 1 |
| Van Wauwe, JP | 1 |
| Janssen, PA | 1 |
| Gundersen, S | 1 |
| Klepp, R | 1 |
| Lund, E | 1 |
| Hart, AA | 1 |
| van der Linden, E | 1 |
| Moolenaar, AJ | 1 |
| Carmichael, J | 1 |
| Dawes, P | 1 |
| Robinson, A | 1 |
| Wilson, R | 3 |
| Crivellari, D | 1 |
| Galligioni, E | 1 |
| Frustaci, S | 1 |
| Gasparini, G | 1 |
| Vaccher, E | 1 |
| Lo Re, G | 1 |
| Talamini, R | 1 |
| Monfardini, S | 1 |
| Poulsen, HS | 1 |
| Mathijs, R | 1 |
| Coolen, D | 1 |
| Hermans-Debaive, C | 1 |
| Fabre, JF | 1 |
| Pourreau-Schneider, N | 1 |
| Martin, PM | 1 |
| Puissant, A | 1 |
| Passalacqua, R | 1 |
| Bella, M | 1 |
| Boogerd, W | 1 |
| van der Sande, JJ | 1 |
| Kröger, R | 1 |
| Somers, R | 1 |
| Tel, W | 1 |
| van Lijf, JH | 1 |
| ten Napel, CH | 1 |
| Hill, M | 1 |
| Lopez, M | 1 |
| Di Lauro, L | 1 |
| Lazzaro, B | 1 |
| Papaldo, P | 1 |
| Sköldefors, H | 1 |
| Theve, NO | 1 |
| Needham, G | 2 |
| Alexieva-Figusch, J | 1 |
| de Jong, FH | 1 |
| Lamberts, WJ | 1 |
| van Gilse, HA | 1 |
| Klign, JG | 1 |
| Essers, U | 1 |
| Petru, E | 1 |
| Schmähl, D | 1 |
| Shaw, MA | 1 |
| Smith, HJ | 2 |
| Wiedemann, G | 1 |
| Canney, PA | 1 |
| Priestman, TJ | 1 |
| Griffiths, T | 1 |
| Latief, TN | 1 |
| Mould, JJ | 1 |
| Spooner, D | 1 |
| D'Souza, A | 1 |
| Donaldson, A | 1 |
| Vincent, MD | 1 |
| Clink, HM | 1 |
| Kandler, R | 1 |
| Elomaa, I | 1 |
| Blomqvist, C | 1 |
| Rissanen, P | 1 |
| Alonso-Muñoz, MC | 1 |
| Ojeda-González, MB | 1 |
| Beltran-Fabregat, M | 1 |
| Dorca-Ribugent, J | 1 |
| López-López, L | 1 |
| Borrás-Balada, J | 1 |
| Cardenal-Alemany, F | 1 |
| Gómez-Batiste, X | 1 |
| Fabregat-Mayol, J | 1 |
| Viladiu-Quemada, P | 1 |
| Tominaga, T | 1 |
| Dogliotti, L | 1 |
| Maschietto, M | 1 |
| Ortega, C | 1 |
| Pieńkowski, T | 1 |
| Zborzil, J | 1 |
| Siedlecki, P | 1 |
| Flis, E | 1 |
| Pałucka, A | 1 |
| Pieńkowska, F | 1 |
| Rubách, M | 1 |
| Piotrowski, J | 1 |
| Huang, HY | 2 |
| Fei, LM | 1 |
| Liu, WH | 1 |
| Ferrari, V | 1 |
| Zaniboni, A | 1 |
| Simoncini, E | 1 |
| Marpicati, E | 1 |
| Montini, E | 1 |
| Moretti, R | 1 |
| Marini, G | 1 |
| Van Deijk, WA | 1 |
| Mellink, WA | 1 |
| Meulenberg, PM | 1 |
| Teichmann, AT | 1 |
| Cremer, P | 1 |
| Wieland, H | 1 |
| Kruse, B | 1 |
| Kuhn, W | 1 |
| Seidel, D | 1 |
| Grem, JL | 1 |
| Falkson, G | 1 |
| Love, RR | 1 |
| Garin, AM | 2 |
| Nadezhdina, TM | 2 |
| Lichinitser, MR | 2 |
| Pokryshkin, VI | 1 |
| Demaille, A | 3 |
| Ghalim, N | 1 |
| Puchois, P | 1 |
| Demarquilly, C | 1 |
| Fruchart, JC | 1 |
| Knuiman, M | 1 |
| Vogel, H | 1 |
| Hahn, RG | 1 |
| Rosenbluth, RJ | 1 |
| Arrigo, C | 1 |
| Nadjafi, C | 1 |
| O'Neill, J | 1 |
| Long, HJ | 1 |
| Chang, MN | 1 |
| Creagan, ET | 1 |
| Coppens, H | 2 |
| Mauriac, L | 2 |
| Rouesse, J | 2 |
| Metz, R | 1 |
| Armand, JP | 2 |
| Mathieu, A | 1 |
| Tubiana, M | 2 |
| Van Cauwenberge, JR | 1 |
| Lambotte, R | 1 |
| Leszczynski, D | 1 |
| Tilson-Mallet, N | 1 |
| Thomas, L | 1 |
| Adcock, H | 1 |
| Bradbeer, J | 2 |
| Brincker, H | 1 |
| Skovgaard-Poulsen, H | 1 |
| Andersen, AP | 1 |
| Loft, H | 1 |
| Andersen, KW | 1 |
| Carbone, PP | 1 |
| Simmonds, MA | 1 |
| White-Hershey, D | 1 |
| Bartholomew, MJ | 1 |
| Walker, BK | 1 |
| Dixon, RH | 1 |
| Valdevia, DE | 1 |
| McKinna, A | 1 |
| Yarnold, J | 1 |
| Walker, KJ | 1 |
| Davies, P | 1 |
| Lê, MG | 1 |
| Maugeri, G | 1 |
| Masselot, J | 1 |
| May-Lévin, F | 1 |
| Sarrazin, D | 1 |
| Vyshinskaia, GV | 1 |
| Bassalyk, LS | 1 |
| Plowman, PN | 2 |
| Rowell, NP | 1 |
| Gilmore, OJ | 1 |
| Dansey, RD | 1 |
| Hesdorffer, CS | 1 |
| Gennatas, CS | 1 |
| Kalovidouris, A | 1 |
| Paraskevas, GA | 1 |
| Kouvaris, J | 1 |
| Trichopoulos, D | 1 |
| Papavasiliou, C | 1 |
| Gorgone, S | 1 |
| Lorenzini, C | 1 |
| Palmeri, R | 1 |
| Belnome, N | 1 |
| Calbo, L | 1 |
| Dattola, P | 1 |
| Melita, P | 1 |
| Zambetti, M | 1 |
| Brambilla, C | 1 |
| Tancini, G | 1 |
| Bonadonna, G | 1 |
| van Tellingen, O | 1 |
| Nooyen, WJ | 1 |
| Mansoor, N | 1 |
| Dansey, R | 1 |
| Miller, AA | 4 |
| Miller, BE | 1 |
| Schmidt, CG | 4 |
| Benz, C | 1 |
| Hollander, C | 1 |
| Miller, B | 4 |
| Wing, LY | 1 |
| Goss, P | 1 |
| Bundred, NJ | 1 |
| Eremin, O | 1 |
| Dale, BA | 1 |
| Bork, E | 1 |
| Hansen, M | 1 |
| Hughes, G | 1 |
| Barrett, AJ | 1 |
| Abusrewil, S | 1 |
| Wilkinson, JR | 1 |
| Williams, JC | 1 |
| Singh, D | 1 |
| Goss, PE | 2 |
| Evans, RG | 1 |
| Dawes, PJ | 1 |
| Daly, MJ | 1 |
| Kempf, H | 1 |
| Faber, P | 1 |
| Kley, HK | 1 |
| van der Heijden, JT | 1 |
| Splinter, TA | 1 |
| Dabag, S | 1 |
| Scharlau, L | 1 |
| Becher, R | 2 |
| Aulbert, E | 1 |
| Hoffmann, B | 1 |
| Anders, CU | 1 |
| Callies, R | 1 |
| Berry, J | 1 |
| Green, BJ | 1 |
| Matheson, DS | 1 |
| Repetto, L | 1 |
| Ardizzoni, A | 2 |
| Gulisano, M | 1 |
| Gardin, G | 1 |
| Fusco, V | 1 |
| Falcone, A | 1 |
| Conte, PF | 1 |
| Paterson, AH | 1 |
| Hedley, DW | 1 |
| Taylor, IW | 1 |
| Levene, AL | 1 |
| Milsted, R | 1 |
| Habeshaw, T | 1 |
| Kaye, S | 1 |
| Sangster, G | 1 |
| Macbeth, F | 1 |
| Campbell-Ferguson, J | 1 |
| Smith, D | 1 |
| Calman, K | 1 |
| Alberto, P | 1 |
| Mermillod, B | 1 |
| Kaplan, E | 1 |
| Obrecht, JP | 1 |
| Jungi, F | 1 |
| Martz, G | 1 |
| Barrelet, L | 1 |
| Cavalli, F | 1 |
| Lionetto, R | 1 |
| Conte, P | 1 |
| Metz, M | 1 |
| Mathieu, M | 1 |
| Van der Wijst, JB | 1 |
| Clarysse, A | 1 |
| Ferrazzi, E | 1 |
| Fournier, C | 1 |
| Caldwell, G | 1 |
| Bradbury, A | 1 |
| Toft, AD | 1 |
| Howell, A | 1 |
| Ribeiro, G | 1 |
| Bradbrook, I | 1 |
| Morrison, P | 1 |
| Rogers, HJ | 1 |
| Sutherland, CM | 1 |
| Muchmore, JH | 1 |
| Carter, RD | 1 |
| Messeih, AA | 1 |
| Macaulay, V | 1 |
| Wright, JC | 1 |
| Kühböck, J | 1 |
| Zielinski, C | 1 |
| Cash, R | 1 |
| Brough, AJ | 1 |
| Cohen, MN | 1 |
| Satoh, PS | 1 |
| Griffiths, CT | 1 |
| Hall, TC | 1 |
| Saba, Z | 1 |
| Barlow, JJ | 1 |
| Nevinny, HB | 1 |
| Givens, JR | 1 |
| Camacho, A | 1 |
| Patterson, P | 1 |
| Hughss, SW | 1 |
| Burley, DM | 1 |
| Eliubaeva, GO | 1 |
| Sanchakova, AV | 1 |
| Vishnevskiĭ, AS | 1 |
| Morales, A | 1 |
| Jalali, S | 1 |
| Garvie, WH | 1 |
| Lyne, C | 1 |
| Gower, DB | 1 |
| Lessof, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal, Hormone Receptor-positive Patients[NCT00309491] | Phase 3 | 2,021 participants (Actual) | Interventional | 1990-12-31 | Completed | ||
| Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
70 reviews available for aminoglutethimide and Breast Cancer
| Article | Year |
|---|---|
Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Female; Humans; Models, Molecular; M | 2015 |
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Hum | 2022 |
Aromatase inhibitors in breast cancer: current and evolving roles.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2002 |
Aromatase inhibitors as adjuvant therapy in breast cancer.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2003 |
Update on the current use of hormonals as therapy in advanced breast cancer.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2003 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2006 |
Aromatase inhibitors: past, present and future in breast cancer therapy.
Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2008 |
Introduction to chemotherapy and antineoplastic pharmacology in breast cancer.
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combina | 1982 |
Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bromocriptine; | 1984 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.
Topics: Adrenalectomy; Adrenocorticotropic Hormone; Aminoglutethimide; Androgens; Aromatase Inhibitors; Brea | 1981 |
[Chemical adrenalectomy induced by aminoglutethimide in the treatment of breast cancer. A review].
Topics: Adrenal Glands; Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female | 1983 |
[Hormone therapy of patients with breast cancer].
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Castration; Combined Modality Therapy; Drug Resi | 1984 |
Chemotherapy of breast cancer.
Topics: Adrenalectomy; Alkylating Agents; Aminoglutethimide; Androgens; Antibiotics, Antineoplastic; Antineo | 1984 |
Beatson: hormones and the management of breast cancer.
Topics: Adult; Aging; Aminoglutethimide; Breast; Breast Neoplasms; Estrogens; Female; Hormones; Humans; Meno | 1982 |
[Hormones and tumor therapy: current clinical status and future developments in endocrine therapy of breast cancer].
Topics: Adrenal Cortex Hormones; Adrenalectomy; Aminoglutethimide; Androgens; Breast Neoplasms; Castration; | 1982 |
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androgens; Breast Neoplasms; Castration; Estrogens; Female; | 1980 |
[Hormonal therapy of breast cancer].
Topics: Aminoglutethimide; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Humans; Medroxyprogeste | 1994 |
Aromatase inhibitors--mechanisms for non-steroidal inhibitors.
Topics: Aminoglutethimide; Animals; Aromatase Inhibitors; Azoles; Breast Neoplasms; Female; Humans; Imidazol | 1994 |
First generation aromatase inhibitors--aminoglutethimide and testololactone.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neop | 1994 |
Clinical use of aromatase inhibitors in the treatment of breast cancers.
Topics: Aminoglutethimide; Animals; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letro | 1993 |
Aromatase, its inhibitors and their use in breast cancer treatment.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast N | 1993 |
Experience with aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Forec | 1993 |
Endocrine therapies of breast cancer.
Topics: Aminoglutethimide; Androgens; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasm | 1996 |
Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Arteriosclerosis; Breast Neoplasms; Cardiovascul | 1997 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormo | 1997 |
A review of endocrine options for the treatment of advanced breast cancer.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 1997 |
[Progestational agents and bone metastasis in breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Dose-Response | 1997 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 1998 |
Pivotal trials of letrozole: a new aromatase inhibitor.
Topics: Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1998 |
[Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 1998 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
Aromatase inhibitors: a dose-response effect?
Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 1999 |
Status of aromatase inhibitors in relation to other breast cancer treatment modalities.
Topics: Aminoglutethimide; Anticarcinogenic Agents; Antineoplastic Agents; Aromatase Inhibitors; Breast Neop | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormo | 1999 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Toleran | 2001 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, | 2002 |
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy | 1977 |
Prolactin and estrogen receptors in breast cancer.
Topics: Aminoglutethimide; Animals; Breast Neoplasms; Dexamethasone; Disease Models, Animal; Estrogen Antago | 1977 |
Cancer of the breast. Endocrine and hormonal therapy.
Topics: Adrenal Cortex Hormones; Adrenalectomy; Adult; Aged; Aminoglutethimide; Antineoplastic Agents; Breas | 1979 |
Adjuvant endocrine therapy of breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 1992 |
Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; F | 1992 |
[Hormone therapy of neoplasms].
Topics: Adenoma, Islet Cell; Aminoglutethimide; Breast Neoplasms; Female; Fluoxymesterone; Humans; Male; Med | 1991 |
Management of breast cancer with bone metastases.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; | 1991 |
[Adjuvant hormone therapy of primary breast cancer. Review of the literature].
Topics: Amenorrhea; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Delayed-Action Preparations; | 1991 |
Clinical use of aromatase inhibitors: current data and future perspectives.
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Estrogen Antagonists; Female | 1990 |
Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Fadrozole; Fe | 1990 |
[Hormonal treatment of breast tumor].
Topics: Adrenalectomy; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Drug Administration Sched | 1990 |
Recent progress in development of aromatase inhibitors.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; C | 1990 |
Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; D | 1990 |
Aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Human | 1989 |
Is there a case for P-450 inhibitors in cancer treatment?
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzym | 1989 |
Clinical use of aromatase inhibitors in the treatment of breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Es | 1988 |
Tamoxifen therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clin | 1987 |
Aminoglutethimide and ketoconazole: historical perspectives and future prospects.
Topics: Adrenal Gland Neoplasms; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Femal | 1988 |
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Male | 1988 |
[Advanced breast cancer treated with aminoglutethimide].
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Humans | 1986 |
Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adult; Aged; Aminoglutethimide; Androgens; Androstenedione; Animal | 1986 |
Fundamental research leading to improved endocrine therapy for breast cancer.
Topics: Adrenal Cortex Hormones; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Combined Modali | 1987 |
[Hormonal and multi-chemotherapeutic treatment in breast cancer. Current therapeutic possibilities].
Topics: Adrenalectomy; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1986 |
Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Topics: 17-Hydroxysteroid Dehydrogenases; Adrenalectomy; Aminoglutethimide; Androstenedione; Animals; Aromat | 1986 |
The clinical investigator and the evolution of the treatment of primary breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1986 |
Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Breast Neoplasms; Estrogen Antagonists; Female; Gonadotropi | 1986 |
Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
Topics: Adrenal Glands; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans | 1985 |
Could aminoglutethimide replace adrenalectomy?
Topics: Adrenal Cortex; Adrenalectomy; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials | 1985 |
[Hormone therapy of metastatic breast carcinoma].
Topics: Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Buserelin; Female; | 1985 |
Aminoglutethimide: a "side-effect" turned to therapeutic advantage.
Topics: Adrenal Cortex Hormones; Adrenal Gland Neoplasms; Adrenal Insufficiency; Adrenocortical Hyperfunctio | 1970 |
94 trials available for aminoglutethimide and Breast Cancer
| Article | Year |
|---|---|
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2013 |
A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone | 2002 |
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Topics: Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 2003 |
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase | 2007 |
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; B | 2008 |
Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1984 |
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Dehydroepiandrosterone; | 1982 |
Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sul | 1983 |
Additive hormonal therapy in women with advanced breast cancer.
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Clinical Trials as Topic; Danazol; Drug Therapy, Com | 1984 |
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone | 1984 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.
Topics: Adrenalectomy; Adrenocorticotropic Hormone; Aminoglutethimide; Androgens; Aromatase Inhibitors; Brea | 1981 |
[Chemical adrenalectomy induced by aminoglutethimide in the treatment of breast cancer. A review].
Topics: Adrenal Glands; Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female | 1983 |
Ablative procedures in patients with metastatic breast carcinoma.
Topics: Adrenal Cortex; Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Clinica | 1984 |
The role of aromatase inhibitors in breast cancer.
Topics: Aged; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1983 |
Currently active protocols in the EORTC Breast Cancer Cooperative Group.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1984 |
Manipulating the hormones.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged | 1984 |
Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Combined Modality Therapy; Estradio | 1984 |
A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Castration; Clinical Trials as Topic; Female; Humans; Menopause | 1982 |
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Res | 1981 |
Aminoglutethimide therapy in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Hypersensitivity; F | 1981 |
A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Hormones; Huma | 1981 |
The treatment of metastatic breast cancer with aminoglutethimide.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance; Female; | 1981 |
Tamoxifen and aminoglutethimide in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Binding, Competitive; Breast Neoplasms; Clinical Trials as Topic; Dr | 1982 |
Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combinatio | 1982 |
Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Hydroc | 1982 |
Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Castration; Clinical Trials as Topic; Drug Admi | 1982 |
Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combinatio | 1982 |
Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone.
Topics: Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Danazol; Drug Therapy, Combination; F | 1982 |
[Aminoglutethimide in metastasizing carcinoma of the breast resistant to hormonal and cytostatic treatment (author's transl)].
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Nause | 1981 |
Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase | 1995 |
Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
Topics: Administration, Oral; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breas | 1995 |
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Resistance; Female; Humans | 1994 |
Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Aged; Aldosterone; Aminoglutethimide; Breast Neoplasms | 1994 |
Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; H | 1993 |
Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Adrenal Cortex Hormones; Aged; Aminoglutethimide; Antineoplastic Ag | 1993 |
A randomized trial on tamoxifen continuation during second-line hormone therapy in breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Middle Aged; Neoplasm Metastasi | 1993 |
Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Female; Humans; Tamoxifen | 1994 |
Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Middle | 1993 |
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Resistance; Female; Humans | 1992 |
[Effectiveness of adjuvant hormone therapy in breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Diethy | 1996 |
Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemothe | 1996 |
[Postoperative hormone therapy of breast cancer (analysis of overall survival)].
Topics: Adult; Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; | 1996 |
Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Humans; Me | 1996 |
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic C | 1997 |
Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Axi | 1997 |
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Androstadienes; Antineoplastic Agents, Hormonal; Antineo | 1997 |
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Topics: Administration, Oral; Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Co | 1998 |
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].
Topics: Aged; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 1999 |
Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2000 |
Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2000 |
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.
Topics: Aged; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Resista | 2001 |
A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Cerebrospinal Fluid Rhinorrhea; Clinical Trials as | 1979 |
Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Huma | 1992 |
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Androstenedione; Antineoplastic Agents; Antineopl | 1992 |
Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Therapy, C | 1992 |
Primary systemic therapy for operable breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aro | 1991 |
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
Topics: Aged; Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Biological Availability; Breas | 1991 |
Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Dehy | 1990 |
Second line hormonal therapy with aminoglutethimide in metastatic breast cancer.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Estrogen An | 1990 |
Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: preliminary results of a double-blind randomized study of the EORTC Breast Cancer Cooperative Group.
Topics: Aminoglutethimide; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Double-Blind Method; Drug Ev | 1990 |
Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Megest | 1989 |
Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Drug Evaluation; | 1989 |
Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Chromatography, High Pressure Liquid; Estrogens; F | 1989 |
Tamoxifen therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clin | 1987 |
[Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Combined Modal | 1987 |
Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.
Topics: Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Medroxyprogesterone; | 1988 |
Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer.
Topics: Aged; Agranulocytosis; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1985 |
Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cl | 1988 |
Endocrine therapy of advanced breast cancer.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Hor | 1988 |
[Early results of hormonal treatment of advanced breast cancer with aminoglutethimide].
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Tr | 1988 |
Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adult; Aged; Aminoglutethimide; Androgens; Androstenedione; Animal | 1986 |
[Use of aminoglutethimide (orimeten) in advanced breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Double-Blind M | 1988 |
[Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast].
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; D | 1987 |
Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cl | 1986 |
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day].
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 1986 |
Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Topics: Adrenalectomy; Aminoglutethimide; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials | 1986 |
A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Doub | 1986 |
Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 1986 |
Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Dose | 1987 |
A randomized trial of aminoglutethimide +/- estrogen before chemotherapy in advanced breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Humans; Hydrocorti | 1987 |
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1987 |
Metastatic pattern and response to endocrine therapy in human breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Diethylstilbestrol; Female; Fluoxymesterone; Humans; Medroxypro | 1986 |
A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1987 |
Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide.
Topics: Aminoglutethimide; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Estrogens; Fe | 1987 |
A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 1985 |
A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therap | 1985 |
Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer.
Topics: Age Factors; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle A | 1985 |
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; F | 1985 |
Could aminoglutethimide replace adrenalectomy?
Topics: Adrenal Cortex; Adrenalectomy; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials | 1985 |
Aminoglutethimide and estrogenic stimulation before chemotherapy for treatment of advanced breast cancer. Preliminary results of a phase II study conducted by the E.O.R.T.C. Breast Cancer Cooperative Group.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ce | 1985 |
Antagonism of aminoglutethimide and danazol in the suppression of serum free oestradiol in breast cancer patients.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Danazol; Estrad | 1985 |
Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aminoglutethimide; Anim | 1967 |
Effect of aminoglutethimide and reserpine on the human pituitary-adrenal axis: remission of a case of Cushing's disease.
Topics: 17-Hydroxycorticosteroids; Addison Disease; Adrenal Glands; Adult; Aldosterone; Aminoglutethimide; A | 1970 |
289 other studies available for aminoglutethimide and Breast Cancer
| Article | Year |
|---|---|
Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Design; Humans; Inhibitory | 2005 |
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
Topics: Aromatase; Biological Products; Breast Neoplasms; Fatty Acids; Female; Humans; Microsomes; Placenta; | 2006 |
Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer.
Topics: Anticarcinogenic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Flavonoids; Huma | 2007 |
Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Gene Expression Regulation, Neoplastic | 2008 |
An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors.
Topics: Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; | 2009 |
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Si | 2010 |
Recognitive nano-thin-film composite beads for the enantiomeric resolution of the metastatic breast cancer drug aminoglutethimide.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, High Pressure | 2014 |
Polymer therapeutics designed for a combination therapy of hormone-dependent cancer.
Topics: Aminoglutethimide; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Dru | 2005 |
Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Antioxidants; Aromatase; Breast Neoplasms; Femal | 2005 |
Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.
Topics: Aminoglutethimide; Antineoplastic Agents; Apoptosis; beta-Cyclodextrins; Breast Neoplasms; Cell Surv | 2007 |
Extended adjuvant therapy for breast cancer--how much is enough?
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Brea | 2007 |
Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
Topics: Adrenocorticotropic Hormone; Aminoglutethimide; Breast Neoplasms; Cosyntropin; Drug Therapy, Combina | 1984 |
Treatment of breast carcinoma with aminoglutethimide.
Topics: Aminoglutethimide; Breast Neoplasms; Cortisone; Dexamethasone; Drug Resistance; Drug Therapy, Combin | 1984 |
Aminoglutethimide.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Neoplasms, Hormon | 1981 |
Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer.
Topics: Adrenocorticotropic Hormone; Aminoglutethimide; Body Weight; Breast Neoplasms; Depression; Drug Admi | 1982 |
Aminoglutethimide-induced hypercholesterolaemia.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hypercholesterolemia; Time Factors | 1984 |
[Variations in gamma-glutamyltranspeptidase levels in patients receiving hormone therapy with aminoglutethimide].
Topics: Aminoglutethimide; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Breast Neoplasms; F | 1984 |
Low-dose aminoglutethimide in treatment of advanced breast cancer.
Topics: Adrenal Glands; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Dehydroepiandrosterone; Drug | 1984 |
A call for caution in the use of aminoglutethimide: negative interactions with dexamethasone and beta blocker treatment.
Topics: Adrenergic beta-Antagonists; Aged; Aminoglutethimide; Brain Neoplasms; Breast Neoplasms; Dexamethaso | 1984 |
Treatment of advanced breast cancer with aminoglutethimide: a 14-year experience.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Dexamethasone; Drug Evaluation; Female; Hormones | 1982 |
Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Nause | 1982 |
Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Menopause; Middle Aged; Neoplas | 1982 |
Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Dizziness; Edema; Female; Fever; Humans; Middle Ag | 1982 |
Metastatic breast cancer in males. Assessment of endocrine therapy.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Humans; Male; Middle Ag | 1984 |
Estrogen receptor status and the clinical response to a combination of aminoglutethimide and cortisol in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Drug Evaluation; Female; Humans; Hydrocortisone; M | 1984 |
Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors.
Topics: Aminoglutethimide; Androgens; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Cyanoketone; | 1982 |
Aminoglutethimide in tamoxifen-resistant patients: The Melbourne Experience.
Topics: Adrenal Glands; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Depression | 1982 |
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Topics: Adult; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandro | 1982 |
[Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Delayed-Action Preparations | 1982 |
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Cos | 1983 |
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Fe | 1984 |
[Medical treatment of the breast].
Topics: Adrenal Cortex Hormones; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Br | 1984 |
Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer.
Topics: Adult; Aged; Aldosterone; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dehydroepiandrosteron | 1984 |
Inhibition of steroid sulfatase activity by danazol.
Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma; Culture Techniques; Danazol; Dehydroepiandrosterone; | 1984 |
[Prognostic value of serum CEA and therapy-induced nonspecific CEA levels in metastasizing breast carcinoma].
Topics: Adult; Aged; Alkaline Phosphatase; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined | 1984 |
The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aminoglutethimide; Antineoplastic Agents; Breast Neopla | 1980 |
The changing role of endocrine therapy in the management of advanced breast cancer.
Topics: Adrenal Glands; Aminoglutethimide; Breast Neoplasms; Bromocriptine; Female; Hormones; Humans; Pituit | 1980 |
Effects of endocrine therapy on steroid-receptor content of breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Estrogen Antagonists; Estrogens, Conju | 1982 |
Response to aminoglutethimide after tamoxifen therapy in advanced breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Drug Administration Sc | 1982 |
Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer.
Topics: Adenocarcinoma; Adult; Aminoglutethimide; Androstenediol; Androstenediols; Breast Neoplasms; Carcino | 1982 |
[Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
Topics: Adrenocorticotropic Hormone; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Delayed-Act | 1982 |
[Pharmacological suppression of the adrenal gland. Considerations on a clinical case].
Topics: Adenocarcinoma, Mucinous; Adrenocortical Hyperfunction; Adult; Aminoglutethimide; Antineoplastic Age | 1982 |
Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Estrogens, Conjugated (USP); Estron | 1982 |
Relationship of cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Cyclic AMP; Cytosol; Female; Humans; M | 1983 |
[A new principle in endocrine therapy of metastatic breast cancer: aminoglutethimide, an antiestrogen with aromatase-inhibiting action].
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Th | 1984 |
[Panmyelopathy induced by aminoglutethimide. Report of a clinical case].
Topics: Aminoglutethimide; Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy | 1984 |
Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Middle | 1983 |
Aminoglutethimide and advanced breast cancer [proceedings].
Topics: Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Female; Humans; Kinetics; Menopause; Re | 1980 |
Potency of the effect of D-stereoisomer of aminoglutethimide on adrenal and extraadrenal steroidogenesis.
Topics: Adrenal Glands; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydr | 1980 |
Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer.
Topics: Adrenal Glands; Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone | 1981 |
Severe thrombocytopenia following the administration of aminoglutethimide.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Middle Aged; Thrombocytopenia | 1984 |
Aminoglutethimide-induced bone marrow injury. Report of a case and review of the literature.
Topics: Adenocarcinoma; Aminoglutethimide; Bone Marrow; Breast Neoplasms; Female; Humans; Middle Aged; Sepsi | 1984 |
Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamid | 1984 |
Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antipyrine; Breast Neoplasms; Chromatography, High Pressure Liquid; | 1984 |
Aminoglutethimide-induced leukopenia: a case report and review of the literature.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Follow-Up Studies; Humans; Hydrocortisone; Leukop | 1984 |
Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Menopause; Middle Aged; Thyrotr | 1984 |
Severe leukopenia induced by aminoglutethimide.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Leukopenia | 1984 |
[Treatment of advanced breast cancer with aminoglutethimide].
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans | 1984 |
[Treatment of metastatic breast cancer with aminoglutethimide after failure of tamoxifen].
Topics: Aminoglutethimide; Breast Neoplasms; Humans; Neoplasm Metastasis; Tamoxifen | 1984 |
Aminoglutethimide as an aromatase inhibitor in the treatment of cancer.
Topics: Aminoglutethimide; Androgens; Animals; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Hu | 1984 |
Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
Topics: Aminoglutethimide; Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estr | 1984 |
[Remission of cutaneous metastases of breast therapy cancer during aminoglutethimide (Orimeten)].
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Skin Neoplasms | 1983 |
[Chemical adrenalectomy--a new alternative in the treatment of advanced breast cancer].
Topics: Adrenal Glands; Aminoglutethimide; Breast Neoplasms; Female; Humans; Testolactone; Testosterone Cong | 1983 |
Biological significance of aromatase activity in human breast tumors.
Topics: Aminoglutethimide; Androstenedione; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrone; Fema | 1983 |
Aminoglutethimide for the treatment of advanced postmenopausal breast cancer.
Topics: Adult; Age Factors; Aged; Aminoglutethimide; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combin | 1983 |
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Hormones; Humans; Me | 1983 |
Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer.
Topics: 6-Ketoprostaglandin F1 alpha; Aminoglutethimide; Breast Neoplasms; Dinoprost; Female; Humans; Menopa | 1983 |
Breast cancer drug adrenalectomy 'passes'.
Topics: Adrenal Glands; Aminoglutethimide; Breast Neoplasms; Female; Humans | 1984 |
Determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma by reversed-phase liquid chromatography.
Topics: Aminoglutethimide; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Interactions; Humans | 1984 |
Resistance of the ovary to blockade of aromatization with aminoglutethimide.
Topics: Adult; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Female; Follic | 1980 |
Choosing treatment for metastatic breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Hormones; Humans; Middle Aged; Neoplasm Metastasi | 1982 |
Aminoglutethimide and dexamethasone therapy (medical adrenalectomy) for metastatic breast carcinoma.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Breast Neoplasms; Dexamethasone; Female; Follow-Up Studies; | 1983 |
Prognostic significance of serum prolactin levels in advanced breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Danazol; Drug Therapy, Combination; Female; Humans; Menopause; | 1983 |
Assessment of response of bone metastases to systemic treatment in patients with breast cancer.
Topics: Alkaline Phosphatase; Aminoglutethimide; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Breast | 1983 |
Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
Irreversible thrombocytopenia following aminoglutethimide.
Topics: Aminoglutethimide; Bone Marrow; Breast Neoplasms; Carcinoma; Female; Humans; Middle Aged; Thrombocyt | 1983 |
Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen.
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Receptors, Estrogen; Skin Neopl | 1981 |
Aminoglutethimide vs. surgical adrenalectomy in breast cancer.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Female; Humans | 1982 |
Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Glucocorticoids; Humans; Menopaus | 1982 |
Medical adrenalectomy in patients with advanced breast cancer.
Topics: Adrenal Glands; Adrenalectomy; Adult; Aminoglutethimide; Breast Neoplasms; Dexamethasone; Female; Fl | 1982 |
Introduction to the conference, Aromatase: New Perspectives for Breast Cancer.
Topics: Aminoglutethimide; Animals; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Estrogens; | 1982 |
Overview of recent development of aromatase inhibitors.
Topics: Aminoglutethimide; Androstatrienes; Androstenedione; Animals; Aromatase Inhibitors; Breast Neoplasms | 1982 |
Basic studies on aminoglutethimide.
Topics: Adrenalectomy; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Castration; Cholesterol; C | 1982 |
Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Topics: Adrenal Glands; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Castration; Estradiol; Es | 1982 |
In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Topics: Adrenal Cortex; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Dexamethasone; Drug Admin | 1982 |
Significance of aromatase activity in human breast cancer.
Topics: Adrenalectomy; Aminoglutethimide; Aromatase; Breast Neoplasms; Estradiol; Estriol; Estrogens; Female | 1982 |
Comparative studies of aromatase inhibitors in cultured human breast cancer cells.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Cell Line; Dihydrotestos | 1982 |
Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Topics: Adrenalectomy; Aminoglutethimide; Androgens; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryoni | 1982 |
Aminoglutethimide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dexamethasone; Drug Therapy, Combi | 1982 |
Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.
Topics: Age Factors; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Evaluation; Drug Therapy, Com | 1982 |
Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Evaluation; Female; Follow-Up Studies; Humans; Middle Aged | 1982 |
Closing remarks to the conference, Aromatase: New Perspectives for Breast Cancer.
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Forecasting; Humans; O | 1982 |
Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
Topics: Aminoglutethimide; Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dana | 1982 |
The medical management of breast cancer.
Topics: Adjuvants, Pharmaceutic; Adult; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Castrati | 1982 |
A preliminary assessment of an ultrasonic Doppler method for the study of blood flow in human breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Methods; Regional Blood Flow; Tamoxifen; Ultras | 1982 |
Leukopenia associated with aminoglutethimide therapy: a case report.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Leukopenia | 1982 |
Is aminoglutethimide an alternative to adrenalectomy for metastatic carcinoma of the breast?
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; | 1982 |
Use of aminoglutethimide and hydrocortisone as a "medical adrenalectomy" for treatment of breast carcinoma.
Topics: Adrenal Glands; Adrenalectomy; Aminoglutethimide; Aromatase Inhibitors; Biological Availability; Bre | 1982 |
[Treatment of metastasizing breast cancer with aminoglutethimide].
Topics: Aged; Aminoglutethimide; Ataxia; Breast Neoplasms; Carcinoembryonic Antigen; Drug Resistance; Estrad | 1982 |
Treatment of metastatic breast cancer with aminoglutethimide.
Topics: Aminoglutethimide; Breast Neoplasms; Dexamethasone; Female; Hormones; Humans; Middle Aged; Nausea; N | 1981 |
Aminoglutethimide.
Topics: Adult; Aminoglutethimide; Breast Neoplasms; Cushing Syndrome; Female; Humans | 1981 |
Less toxic treatment for advanced breast cancer.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Estrogens; Female; Humans; Tamoxifen | 1981 |
[Aminoglutethimide - a new drug for the after care in breast cancer].
Topics: Aminoglutethimide; Breast Neoplasms; Dexamethasone; Drug Therapy, Combination; Female; Half-Life; Hu | 1981 |
Medical adrenalectomy with aminoglutethimide-cortisol in the treatment of metastatic breast carcinoma.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Hydrocortisone | 1980 |
Aminoglutethimide in the management of advanced breast cancer.
Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Liver Neoplasms; Lung Neo | 1980 |
Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Drug Resistance; Estrog | 1981 |
Cancer of the breast: the past decade (second of two parts).
Topics: Adrenalectomy; Adult; Age Factors; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Castr | 1980 |
Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Neoplasms, Hormone-Depe | 1980 |
Medical adrenalectomy may replace surgery for advanced breast cancer.
Topics: Adipose Tissue; Adrenal Glands; Adrenalectomy; Aminoglutethimide; Androstenedione; Breast Neoplasms; | 1980 |
Systemic lupus erythematosus induced by aminoglutethimide.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged | 1980 |
Inhibition of androgen aromatization in human breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Carbon Radioisotopes; Es | 1980 |
Aminoglutethimide in the management of metastatic breast cancer.
Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dexamethasone; Drug Therapy, Combination; | 1980 |
Clinical and radiographic correlations in breast cancer patients with osseous metastases.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Age | 1981 |
[The adjuvant hormonal therapy of breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Diethy | 1995 |
[Use of aminoglutethimide in the hormonal treatment of patients with advanced breast cancer].
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; | 1994 |
Dual pharmacological effect of aminoglutethamide.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Lupus Erythematosus, Systemic | 1994 |
Megestrol acetate in advanced breast carcinoma.
Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Cross-Over Studies; Female | 1994 |
Neutropenia induced by aminoglutethimide in breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Neutropenia | 1993 |
Reduced occurrence of mdr-1 amplification in stage-IV breast-cancer patients treated with tamoxifen compared with other endocrine treatments.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 1993 |
Effect of aminoglutethemide on the activity of a case of a connective tissue disorder with features of systemic lupus erythematosus.
Topics: Aged; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Connective Tissue Diseases; Female; | 1993 |
Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Antineoplastic Agents; Antineoplastic Combined Chem | 1994 |
Factors influencing aromatase activity in the breast.
Topics: Adipose Tissue; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast | 1993 |
Response to third-line endocrine treatment for advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; B | 1993 |
[Aromatase inhibitor].
Topics: Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; | 1993 |
Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening.
Topics: Aminoglutethimide; Androstenedione; Androstenols; Antineoplastic Agents; Aromatase; Aromatase Inhibi | 1993 |
Aminoglutethimide (AG) and hydrocortisone (HC) in bone metastases: a retrospective study.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; | 1993 |
Appearance of amplified thymidylate synthase or dihydrofolate reductase genes in stage-IV breast-cancer patients receiving endocrine treatment.
Topics: Aminoglutethimide; Base Sequence; Biopsy, Needle; Breast Neoplasms; DNA, Neoplasm; Drug Resistance; | 1993 |
A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 1995 |
Liquid chromatographic separation and measurement of optical isomers of aminoglutethimide and its acetyl metabolite in plasma, saliva, and urine.
Topics: 1-Propanol; Acetylation; Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chrom | 1995 |
C-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast | 1996 |
Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Blotting, Western | 1996 |
Aromatase inhibitors come of age.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibito | 1997 |
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedi | 1997 |
Aromatase inhibitors for breast cancer--further progress.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 1997 |
Predictors of response to second-line endocrine therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Bre | 1997 |
Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Administration, Topical; Aminoglutethimide; Analysis of Varia | 1997 |
Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients.
Topics: Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; De | 1998 |
Pulmonary eosinophilia associated with aminoglutethimide.
Topics: Adenocarcinoma; Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; | 1998 |
Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.
Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Creatini | 1999 |
Pharmacokinetics of S- and R-enantiomers of aminoglutethimide following oral administration of racemic drug in breast cancer patients.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, H | 1999 |
Clinico-pharmacological aspects of different hormone treatments.
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Toremifene | 2000 |
High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Cell Division | 2001 |
Comparison of in vitro exemestane activity versus other antiaromatase agents.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Choriocarcin | 2000 |
Aminoglutethimide in treatment of metastatic breast carcinoma.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neopl | 1978 |
Aminoglutethimide in breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Evaluation; Female; Humans | 1978 |
Mechanism of action of aminoglutethimide in breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Estradiol; Estrogen Antagonists; | 1979 |
[Breast neoplasms: endocrine therapy and importance of steroid hormone receptors].
Topics: Aminoglutethimide; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Receptors, Progesterone; | 1979 |
Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Topics: 17-alpha-Hydroxypregnenolone; Aminoglutethimide; Androgens; Androstenedione; Breast Neoplasms; Castr | 1978 |
Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aminoglutethimide; Breast Neoplasms; Castration; Dehydr | 1977 |
In vitro effects of theophylline and aminogluthetimide upon basal and ACTH induced cAMP levels and steroid output by the normal human adrenal gland.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Breast Neoplasms; Cycli | 1978 |
Pancytopenia induced by aminoglutethimide in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; | 1978 |
Breast carcinoma associated with Klinefelter syndrome: a case report.
Topics: Adrenal Glands; Adult; Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; | 1978 |
Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.
Topics: Adult; Aminoglutethimide; Androstenedione; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; | 1978 |
Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide.
Topics: Adult; Aminoglutethimide; Breast Neoplasms; Chlorpromazine; Female; Follicle Stimulating Hormone; Hu | 1977 |
In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women.
Topics: Aminoglutethimide; Blood Specimen Collection; Breast Neoplasms; Female; Hirsutism; Humans; Medroxypr | 1979 |
Medical adrenalectomy and plasma steroids in advanced breast carcinoma.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Adrenalectomy; Aminoglutethimide; Androstenedione; Breast N | 1978 |
Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.
Topics: Adrenal Cortex; Adrenalectomy; Aldosterone; Aminoglutethimide; Androstenedione; Bone Neoplasms; Brea | 1978 |
Experience with 6-aminoglutethimide in the treatment of metastatic breast cancer.
Topics: Adrenal Glands; Aminoglutethimide; Betamethasone; Breast Neoplasms; Drug Therapy, Combination; Femal | 1978 |
Medical and surgical adrenalectomy in patients with advanced breast carcinoma.
Topics: Adrenal Glands; Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Dexamethasone; Fema | 1977 |
Aminoglutethimide for metastatic breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Neoplasm Metastasis | 1977 |
Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
Topics: Adrenal Glands; Aminoglutethimide; Androstenedione; Breast Neoplasms; Castration; Estradiol; Estroge | 1977 |
Studies in patients with metastatic breast carcinoma treated with aminoglutethimide for medical adrenalectomy.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Dexamethasone; Drug Therapy, Combination; Female | 1976 |
Letter: Amino-glutethimide.
Topics: Adrenal Glands; Aminoglutethimide; Breast Neoplasms; Humans | 1975 |
Letter: Medical adrenalectomy with aminoglutethimide.
Topics: Adrenal Glands; Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Female; Humans | 1975 |
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Female; Follow- | 1992 |
[Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminoglutethimide; Androstenedione; Breast Neo | 1992 |
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Drug Admi | 1992 |
Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Buserelin; Cortisone; Female; Goserelin; | 1992 |
Low-dose aminoglutethimide therapy without glucocorticoid administration. Clinical and hormonal findings.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Glucocorticoids; Hormones; Humans; Menopause; Mid | 1992 |
Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Aminoglutethimide; Androstenedione; Breas | 1991 |
Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.
Topics: Aminoglutethimide; Androstenedione; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Es | 1991 |
[Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Follow-Up Studies; Huma | 1991 |
Characterisation of metabolites of 3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione, a potential breast cancer drug.
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Fe | 1991 |
[The use of aminoglutethimide in the treatment of metastatic breast cancer].
Topics: Adrenal Glands; Age Factors; Aminoglutethimide; Androstenedione; Breast Neoplasms; Female; Humans; M | 1991 |
[Growth inhibition of MCF-7 human breast cancer cells by aromatase inhibitors].
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; | 1991 |
[Reflexions on hormone therapy of cancer of the breast].
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Humans; Medroxyprogesterone Aceta | 1991 |
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogens, Conjugated (USP); | 1991 |
pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.
Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Immuno | 1991 |
Direct enantiomeric high performance liquid chromatographic separation of aminoglutethimide and its major metabolite on a series of Chiralcel OD and Chiralcel OJ columns and its application to biological fluids.
Topics: Aminoglutethimide; Body Fluids; Breast Neoplasms; Carbamates; Cellulose; Chromatography, High Pressu | 1991 |
Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.
Topics: Adult; Aged; Aminoglutethimide; Analysis of Variance; Biological Availability; Breast Neoplasms; Chr | 1991 |
[Hormonal control of disseminated breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Delayed-Action Preparations; Estrogen An | 1990 |
Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1990 |
Endocrine and clinical aspects of new compounds for treatment of hormone-related cancer in gynecology.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Buserelin; Female; Goser | 1990 |
Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1990 |
Radiotherapy enhances the toxicity of aminoglutethimide.
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Drug E | 1990 |
Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.
Topics: Administration, Oral; Aged; Aminoglutethimide; Breast Neoplasms; Drug Interactions; Female; Humans; | 1990 |
[Experiences with Rodazol therapy in the treatment of postmenopausal patients with metastatic breast cancer].
Topics: Administration, Oral; Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; Female; Fol | 1990 |
Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 1990 |
Relationship between tumour aromatase activity, tumour characteristics and response to therapy.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Estr | 1990 |
Response to second-line hormone treatment for advanced breast cancer. Predictive value of ploidy determination.
Topics: Aminoglutethimide; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dip | 1990 |
[Aromatase activity in lymphocytes of cancer patients and healthy subjects].
Topics: Adenofibroma; Adult; Aged; Aminoglutethimide; Androgens; Aromatase; Breast Neoplasms; Colonic Neopla | 1990 |
Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.
Topics: Aminoglutethimide; Antipyrine; Aromatase Inhibitors; Breast Neoplasms; Digitoxin; Drug Interactions; | 1990 |
Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy.
Topics: Aminoglutethimide; Antibodies, Monoclonal; Breast Neoplasms; Combined Modality Therapy; Dextrans; Fe | 1986 |
[Palliative treatment of skeletal metastases in patients with breast carcinoma].
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Megestrol; Neoplasm Metastasis; Palliative Care | 1987 |
Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; ErbB Receptors; Fema | 1989 |
Aminoglutethimide in patients with metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Fema | 1989 |
Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Buserelin; Female; Goserelin; Humans; Menopaus | 1989 |
Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Estrogens, Conjugated (USP); Estrone; Female; Humans; Mid | 1989 |
Aminoglutethimide-induced hyperkalaemia.
Topics: Adenocarcinoma; Aminoglutethimide; Breast Neoplasms; Female; Humans; Hyperkalemia; Middle Aged; Time | 1989 |
Separation of urinary metabolites of radiolabelled estrogens in man by HPLC.
Topics: Aminoglutethimide; Breast Neoplasms; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Est | 1989 |
[Current status of hormonotherapy of metastatic cancer of the breast].
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Humans; Hydrocortisone; Medroxypr | 1989 |
Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1989 |
Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; B | 1989 |
Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diethylst | 1989 |
Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition.
Topics: Adult; Aged; Aminoglutethimide; Analysis of Variance; Aromatase Inhibitors; Breast Neoplasms; Estron | 1989 |
Agranulocytosis induced by aminoglutethimide.
Topics: Aged; Agranulocytosis; Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; | 1988 |
[Dosage and modulation of cutaneous steroid receptors during antihormonal therapy in a case of Stewart-Treves syndrome].
Topics: Adenocarcinoma; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Immunoenzyme Techniques; | 1988 |
Low-dose aminoglutethimide and aromatase inhibition.
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Oxidoreductases | 1985 |
Aminoglutethimide in advanced breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Aminoglutethimide; Breast Neoplasms; Female; gamma-Glutamyltransf | 1985 |
Effective systemic therapy for spinal epidural metastases from breast carcinoma.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 1989 |
[Transient bone marrow inhibition caused by aminoglutethimide].
Topics: Adenocarcinoma; Aminoglutethimide; Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Female; H | 1989 |
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroep | 1985 |
Hormonal treatment of disseminated male breast cancer.
Topics: Adult; Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Breast Neoplasms; Castration; | 1985 |
[Value of hormone therapy in metastasizing breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medroxyprogesterone; Med | 1985 |
Endocrine treatment of breast cancer: effects upon intratumoral estrone sulfate metabolism and peripheral steroid levels.
Topics: Aminoglutethimide; Breast Neoplasms; Danazol; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate | 1986 |
Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1986 |
Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brea | 1986 |
[Endocrine therapy of breast cancer].
Topics: Aminoglutethimide; Antibodies, Monoclonal; Breast Neoplasms; Combined Modality Therapy; Female; Horm | 1987 |
Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
Topics: Aged; Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1987 |
On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Dose-Response | 1987 |
[Which hormone therapy should be used in advanced breast carcinoma in males?].
Topics: Adenocarcinoma; Aged; Aminoglutethimide; Axilla; Breast Neoplasms; Dexamethasone; Drug Evaluation; H | 1988 |
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Topics: Adrenocorticotropic Hormone; Aged; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast | 1985 |
Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; | 1985 |
Aminoglutethimide as second line therapy in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brea | 1986 |
[Recent progress in endocrine therapy of patients with breast cancer].
Topics: Aminoglutethimide; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Pituitary Hormone-Releasi | 1988 |
[Endocrine therapy in breast carcinoma].
Topics: Adrenal Cortex Hormones; Adrenalectomy; Adult; Aminoglutethimide; Antineoplastic Combined Chemothera | 1988 |
[Experience in treating 20 cases of postmenopausal advanced breast cancer].
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Thoracic N | 1986 |
Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations.
Topics: Adult; Aminoglutethimide; Breast Neoplasms; Buserelin; Cortisone; Drug Evaluation; Drug Therapy, Com | 1988 |
Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Medr | 1985 |
[Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
Topics: Aminoglutethimide; Breast Neoplasms; Cholesterol; Cortisone; Drug Therapy, Combination; Female; Huma | 1985 |
A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1988 |
Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; ErbB Receptors; Female; Humans; Hydroc | 1988 |
Variations in lipoproteins during aminoglutethimide therapy.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Lipoproteins; Time Factors | 1987 |
Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Estradiol; Estrogens; Estrone; Humans; Male; Middle Aged; | 1987 |
Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
[Therapeutic results obtained with aminoglutethimide in advanced-stage breast cancer. Factors predictive of a response].
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Es | 1986 |
Clinical studies with aminoglutethimide in advanced breast carcinoma.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation | 1986 |
Aminoglutethimide: chemistry, pharmacokinetics, pharmacology and mechanism of action.
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Chemical Phenomena; Chemistry; Coumarins | 1986 |
Mammary steroidogenesis: therapeutic implications.
Topics: 17-Hydroxysteroid Dehydrogenases; Adipose Tissue; Aminoglutethimide; Androstenedione; Aromatase; Aro | 1987 |
[Factors linked to the development of pleuro-pulmonary metastases in breast cancer. Preliminary study].
Topics: Aminoglutethimide; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Pleu | 1987 |
[The use of aminoglutethimide (orimeten) in disseminated breast cancer].
Topics: Adult; Aminoglutethimide; Breast Neoplasms; Female; Follow-Up Studies; Humans; Menopause; Middle Age | 1987 |
Aminoglutethimide: a toxic object lesson in the endocrine management of cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans | 1987 |
Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Middle Aged; Neopl | 1987 |
Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Evaluation Stud | 1987 |
[Aminoglutethimide in the treatment of metastasizing breast carcinoma in old age].
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged | 1987 |
Aminoglutethimide therapy in breast cancer: relationship of blood levels to drug-related side effects.
Topics: Aminoglutethimide; Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Humans; Urticaria | 1987 |
Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Men | 1987 |
Improved method for the quantification of aminoglutethimide in urine samples.
Topics: Aminoglutethimide; Biotransformation; Breast Neoplasms; Chromatography, High Pressure Liquid; Female | 1987 |
Endocrine therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Neoplasm Metastasis; Ovariectomy; Progesterone | 1987 |
Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Foll | 1987 |
Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines.
Topics: Aminoglutethimide; Animals; Azasteroids; Breast Neoplasms; Cell Cycle; Cell Line; Danazol; Dexametha | 1986 |
Aromatase inhibitors and the treatment of breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Animals; Aromatase Inhibitors; Breast Neoplasms; Es | 1986 |
Beneficial response to pituitary ablation following aminoglutethimide.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Hypophysectomy; Middle Aged; Tamox | 1986 |
Severe hyponatremia following simultaneous administration of aminoglutethimide and diuretics.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Diuretics; Drug Interactions; Drug Therapy, Combination; | 1986 |
The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer.
Topics: Administration, Oral; Aminoglutethimide; Breast Neoplasms; Dose-Response Relationship, Drug; Female; | 1986 |
Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies.
Topics: Agranulocytosis; Aminoglutethimide; Bone Marrow; Breast Neoplasms; Female; Granulocytes; Humans; Mac | 1986 |
Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response.
Topics: Aminoglutethimide; Androstenedione; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast | 1986 |
Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Resp | 1986 |
2nd Scandinavian Breast Cancer Symposium. Bergen, Norway, May 23-24, 1985.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans | 1986 |
Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; Estradiol; Estrogens; Estrone; Fe | 1986 |
Pharmacology of aminoglutethimide: structure/activity relationships and receptor interactions.
Topics: Aminoglutethimide; Androgens; Aromatase Inhibitors; Breast Neoplasms; Chemical Phenomena; Chemistry; | 1986 |
Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Evaluation; Female; Hormones; | 1986 |
Role of aminoglutethimide in male breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrone; Humans; Hydrocor | 1986 |
Aminoglutethimide-induced myelosuppression.
Topics: Adenocarcinoma; Aged; Agranulocytosis; Aminoglutethimide; Breast Neoplasms; Female; Humans | 1986 |
[Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer].
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; | 1986 |
[Low-dose aminoglutethimide therapy without cortisol substitution in postmenopause metastasizing breast cancer].
Topics: Aminoglutethimide; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; Huma | 1986 |
Biochemical basis for the antagonism between aminoglutethimide and danazol in the endocrine treatment of breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Danazol; Estrad | 1986 |
Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Cell Line; Cytotoxicity, Immunologic; Estradiol; Female; | 1987 |
Metastatic breast cancer: an analysis of prognostic factors in patients treated with aminoglutethimide.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Ovariectom | 1987 |
Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer.
Topics: Adult; Aminoglutethimide; Breast Neoplasms; Cortisone; Female; Humans; Menopause; Middle Aged; Neopl | 1986 |
Chemotherapy and hormone therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1985 |
Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism.
Topics: Aminoglutethimide; Breast Neoplasms; Chromatography, High Pressure Liquid; Colorimetry; Female; Huma | 1985 |
Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DN | 1985 |
[Aminoglutethimide-induced dyslipemia. Clinical study].
Topics: Aminoglutethimide; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Breast Neoplasms; Chole | 1985 |
Aminoglutethimide induced agranulocytosis in breast cancer.
Topics: Aged; Agranulocytosis; Aminoglutethimide; Breast Neoplasms; Female; Humans | 1985 |
Management of advanced carcinoma of the breast.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1985 |
Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Administration | 1985 |
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Topics: Aged; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estrone; Female; H | 1985 |
Response to aminoglutethimide after failure of tamoxifen therapy in breast cancer.
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Middle Ag | 1985 |
Aminoglutethimide-induced hematologic toxicity: worldwide experience.
Topics: Aminoglutethimide; Blood Cell Count; Breast Neoplasms; Female; Global Health; Hematologic Diseases; | 1985 |
Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Cortisone; Female; Fludrocortisone; Humans; Menopa | 1985 |
Comparison of different endocrine therapies in management of bone metastases from breast carcinoma.
Topics: Adrenal Cortex Hormones; Adrenalectomy; Aminoglutethimide; Androgens; Bone Neoplasms; Breast Neoplas | 1985 |
Update in cancer chemotherapy: general considerations and breast cancer, Part I.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aminoglutethimide; Androgens; Breast Neoplasms; Estrogen Antag | 1985 |
[Aminoglutethimide therapy in advanced breast cancer].
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Middle | 1985 |
Preliminary trial of aminoglutethimide in breast cancer.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Administration, Oral; Aminoglutethimide; Antineoplastic | 1973 |
Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer.
Topics: Adrenal Glands; Adrenalectomy; Adult; Aged; Aminoglutethimide; Binding, Competitive; Breast Neoplasm | 1974 |
[Reduced excretion of total gonadotropins during use of Elipten in breast neoplasms].
Topics: 17-Ketosteroids; Adult; Aminoglutethimide; Aniline Compounds; Anticonvulsants; Breast Neoplasms; Fem | 1972 |
Enhancement of lymphocyte production by adrenocortical inhibition.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Aminoglutethimide; Aniline Compounds; Animals; Anticonvulsa | 1972 |
The effects of aminoglutethimide and prednisolone on steroid excretion in cases of carcinoma of the breast.
Topics: Aminoglutethimide; Aniline Compounds; Anticonvulsants; Breast Neoplasms; Estrogens; Female; Glucocor | 1971 |